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ABSTRACT 
A Paper-Based ELISA Device for the Rapid Detection of Ischemic Stroke 
Andrea Elisabeth Larsen 
Diagnosing an ischemic stroke accurately and quickly is essential for appropriate 
treatment and results in more effective management of the stroke, leading to better patient 
outcomes. Specifically, the determination of ischemic versus hemorrhagic stroke leads to 
critically different treatment paths, which would be potentially fatal if administered 
incorrectly. Currently, ischemic strokes are diagnosed through a series of tests, including a 
physical examination, CT scans, and a panel of blood tests to exclude hemorrhagic stroke 
or other similarly presenting conditions, in order to administer tPA (the main treatment) 
within the three hour window.  
The discovery of biomarkers, molecules which are upregulated during the onset of 
a specific condition or disease, can be used to diagnose patients when integrated with an 
appropriate platform. The objective of this thesis was to further develop a paper-based 
microfluidic device for the rapid detection of ischemic stroke using biomarkers that can be 
detected in the blood. This device uses HRP-based enzyme linked immunosorbent assay 
(ELISA) technology on a cellulose paper surface to yield a sensitive (11.8 pM) assay 
targeting S100B, a protein released by glial cells in the brain during stroke. Wax printing 
allows for creation of precise hydrophilic pathways in which sample fluid can travel within 
the 3D microfluidic device to react with a variety of proteins and reagents.  
This technology has the potential to be implemented globally as a point-of-care 
device for use in developing countries without consistent or reliable access to advanced 
diagnostic technology. The device is cheap to produce, portable, and results can be 
determined quickly and qualitatively analyzed using cell phone images, making it an 
accessible technology for patients around the globe. 
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1. INTRODUCTION 
 
 Specific Goals of this Thesis Project and Report 
 The purpose of this thesis project and associated report is to enable a paper-based 
approach to an enzyme-linked immunosorbent assay (ELISA). The main objective is to 
fully integrate reagents in the device to minimize the time and effort required by the user. 
This assay will be loaded with reagents that are able to bind to and detect the presence of 
biomarkers in a patient sample in order to diagnose a specific pathology. Onboard reagents, 
e.g. reagents that are included on the assay as opposed to added from liquid by the user, 
will allow for overall simplification of the test device and potential for use in developing 
countries due to the lower cost and rugged design. At the project’s completion, we will 
have shown that an ELISA-like assay can be run in a paper-based format with onboard 
reagents for specific biomarker detection. We will accomplish this goal by: 
• Design a full multi-layer paper-chip for an ELISA-like assay  
• Design a housing component to apply the appropriate pressure to mediate fluid 
transfer between layers  
• Design and apply onboard conjugate reagent  
• Assemble device in housing and test fluid connectivity via dye tests 
• Redesign chip and housing component and optimize fluid connectivity via dye tests 
• Demonstrate ELISA-like assay on chip using antibodies and antigens 
• Quantify the signal to demonstrate a standard ladder using smart phone image 
analysis  
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 Molecular Diagnostics Technology 
Molecular diagnostics is broadly defined as the study of the specific biological 
markers within a patient’s genome and/or proteome in order to derive a conclusion about 
patient health. These tests can yield diagnostic information about a patient’s genetic 
makeup, gene expression, potential or current disease states, and genetic mutation 
detection. Originally, these techniques were used in a research laboratory setting and have 
recently begun to make their way into the clinical diagnostics realm due to high accuracy, 
repeatability, ease of use, and low-cost manufacturing potential all while quickly providing 
information about the patient’s diagnosis. This diagnosis can lead to quick treatments and 
preventative care, improving patient outcomes and overall quality of care.  
Molecular diagnostics includes experimental analyses from a variety of techniques, 
including polymerase chain reaction (PCR), microarray chips, and biological assays [1]. 
PCR uses the mechanisms behind DNA synthesis in order to target and amplify specific 
pathogenic DNA sequences resulting in millions of identical DNA copies [2]. This 
technique can be used to detect viruses, bacteria, and specific genetic sequences in the 
patient’s genome in order to determine if the patient is suffering from a viral or bacterial 
infection or accurately diagnose many genetic diseases [2]. As a downside, PCR requires 
a skilled user and investment in high-cost equipment. Microarrays invoke a similar 
property of nucleotide bonding. A patient’s mRNA is isolated from a sample, converted to 
cDNA, and labeled with a fluorescent probe. DNA is bound to the bottom of the microarray 
plate and the patient’s sample is incubated over it, allowing the patient’s cDNA to bind to 
the fixed DNA. Fluorescent dye intensity indicates the quantity of cDNA bound to that 
corresponding DNA sequence of interest. However, the bioinformatics/statistical analysis 
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workload generated by high-density microarrays is very taxing [3]. The technologies 
within the assay category are often looking at the proteins expressed by the patient’s 
genetic code, rather than the genetic code itself. Assays are currently developed in several 
forms to target specific biomarkers, which are any type of substance whose presence 
indicates a disease, infection, or other type of physiological characteristic [4]. Assays 
function on the basis of antigen-antibody bonding characteristics wherein a biomarker 
(antigen) can be detected using the specific and unique antibody to which it binds. These 
assays can be costly to develop because the antigen-antibody pair must be experimentally 
determined but they follow a similar design across different diagnoses.  
 
 Enzyme Linked Immunosorbent Assay (ELISA) 
The Enzyme Linked Immunosorbent Assay (ELISA) was developed in the 1970s 
to target and detect specific analytes in a sample, including antibodies, antigens, proteins 
and glycoproteins [5]. Typically, ELISAs are run in the lab on 96-well plates due to the 
fact that the test method requires several wash steps, which must be run in a microplate 
washer and further analyzed on a microplate reader. There are several different types of 
ELISAs including direct, indirect, sandwich, and competitive ELISAs, which refer to the 
orientation of the antigen-antibody binding that occurs and which portion of the reaction is 
immobilized on the plate. Each of these reactions can be seen in Figure 1 below, which 
illustrates the difference of binding order between the types of ELISA.  
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Figure 1. Four commonly used formats for an ELISA [6] 
The antigen is the protein of interested and is designated with a green circle. The 
orange circle is a reactive enzyme which is used to cause a fluorescent or chromogenic 
reaction, directly indicating a positive binding result. The substrate is a red star which is 
what the enzyme reacts with in order to produce said fluorescence or color change. Direct 
and indirect ELISAs both begin with the antigen immobilized with direct adsorption to the 
bottom of the plate and then is detected using either one or two antibodies. Direct detection 
is the least accurate of the four types of ELISA but is quite common for 
immunohistochemical staining of tissues and cells [7]. The indirect ELISA is more specific 
than the direct ELISA because the secondary antibody conjugate provides another level of 
specificity to the primary conjugate antibody to ensure accuracy. Competitive ELISA is 
commonly used when the antigen is small and has only one epitope [7]. This type of ELISA 
involves the unlabeled antigens from the sample competing with labeled antigens (the red 
“inhibitor antigen,” above) that are added to the plate to bind to the capture antibody. In 
this case, the presence of the antigen in the sample lowers the intensity of the color signal 
because the labeled antigens will have been forced to unbind and then subsequently washed 
out. 
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Sandwich ELISAs are the most commonly used ELISAs to detect an antigen in 
solution because it is highly specific, very sensitive, and is able to detect an antigen without 
pretreatment of a complex sample. When referring to diagnostic tests, sensitivity is the 
ability of the test to correctly report positive results, whereas specificity is the ability of the 
test to correctly report negative results. In this assay, the antigen of interest is sandwiched 
between two antibodies – a capture and a detection antibody. The capture antibody is first 
incubated onto the plate and then the sample is washed over it. Here, the antigens bind, and 
the remainder of the sample is washed out. Then, the plate is incubated with a second 
enzyme-linked detection antibody that binds directly to the antigen, creating a “sandwich” 
of antibodies. Alternatively, the antigen will be bound with an unlabeled conjugate 
antibody which will then itself be detected with another enzyme-linked conjugate antibody. 
In either instance, the labeled antibody has a substrate that will change color, indicating the 
antigen presence [7]. Both types of sandwich ELISA can be seen in Figure 2 below. 
 
Figure 2. Two types of sandwich ELISA, (a) direct sandwich and (b) double sandwich, 
adapted from Zhang, et al [8] 
Monoclonal antibodies are antibodies which all have a paratope against one epitope 
on an antigen. In contrast, polyclonal antibodies are a set of antibodies which have 
paratopes to a variety of epitopes on one antigen. Since ELISAs often use monoclonal 
antibodies, antibodies that bind to a single antigen epitope, they exhibit high specificity for 
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that antigen, resulting in highly accurate tests. This accuracy is only increased with binding 
of additional antibodies within the ELISA because the final result will only indicate the 
reactions which bound every antibody successfully. For example, in the direct ELISA, only 
one antibody needs to bind one antigen to yield a positive result, whereas in the double 
sandwich ELISA, three antibodies needed to bind correctly to show a positive result, 
reducing the chance for a false positive. This higher complexity ELISA is therefore used 
due to the high sensitivity (low number of false negatives) and specificity (low number of 
false positives) [8]. However, even with high specificity, false negatives and positives can 
still occur within these tests. For ELISAs, reasons for false positives include: 
1) Non-specific reaction caused by the secondary antibody 
2) Hydrophobic binding of immunoglobulin components in sample to plastic surfaces  
3) Ionic interaction between immunoglobulin in sample specimens and antigen 
4) Immune-recognition of blocking agents by antibodies in serum specimens [10]. 
All of these would return a positive result even if the target antigen was not present in the 
sample. Further, false negative reactions can occur from:  
1) The competitive inhibition of test antibodies by relevant antibodies in animal serum 
2) Denaturation of enzymes conjugated to detection antibodies [10]. 
These errors would show a negative result despite the target antigen actually being present 
in the sample. Both types of incorrect results would result in misinformed patient diagnosis 
and potentially misdirect further treatment. These test failures can be mitigated against 
using BSA blocking, extensive antibody screening, and reduction or quantification of 
background noise [11]. 
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 Lateral Flow Immunoassays 
Lateral flow immunoassays (LFA) are currently found in a variety of applications, 
including pregnancy tests, urine glucose tests, or tests for diseases like malaria, dengue, 
and typhoid fever [12]. An LFA is usually composed of the following elements: sample 
pad, conjugate release pad, membrane with immobilized antibodies and adsorbent pad. The 
components of the strip are usually fixed to an inert backing material, as seen in Figure 3 
below. 
 
Figure 3. Standard layout for a lateral flow assay [13] 
Typical materials include cast membranes (e.g., nitrocellulose, polyethersulfone), fibrous 
filters (e.g., cellulose, glass fiber, rayon, polyester), filters manufactured from fused 
particles (e.g., polyethylene), and even some woven polymers [14]. The patient sample is 
spotted onto the assay sample pad and then runs along the strip, leading it across the 
conjugate pad where the sample solubilizes the detector reagent with labeled antibodies. 
These antibodies bind to the biomarkers in the sample and later bind to capture antibodies 
on the test line to display the results of the assay. 
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1.4.1 Sample Pad 
The first portion that the sample comes into contact with is the sample pad, which 
is primarily used to collect the entirety of the sample and distribute it across the rest of the 
assay strip at a controlled rate. Lateral flow assays are capable of handling a variety of 
patient samples, including saliva, urine, blood plasma, et. al. These samples all have 
different biological and chemical makeups, from the matrix of constitutive proteins to the 
pH, charge, and viscosity. These properties vary between sample type as well as between 
patients, depending on time of day, diet, age, etc [15]. The physical characteristics of a 
sample allow or prohibit the sample to flow through the entirety of the assay, therefore, an 
optimum set of characteristics exist that make the sample compatible with the assay. These 
parameters vary from assay to assay and can be achieved through a pretreatment process. 
Pretreatment can either occur separately from the assay – e.g. in a centrifuge to separate 
blood components – or on the sample pad itself. Sample treatments can include the filtering 
out of particulates or red blood cells, changing the pH of the sample, and/or actively 
binding sample components that can interfere with the assay in order to increase the overall 
sensitivity of the assay, depending on the sample type and the design of the device [14]. 
The treatments can include blocking reagents, proteins, detergents, and surfactants which 
all work toward “normalizing” the sample in the sample pad. Typically, the liquid treatment 
reagents and/or buffers are added onto the sample pad and allowed to dry down. 
 The material options for the sample pad allow for variability in sample volume, 
efficacy of pretreatment, and overall control of the sample. Two of the main characteristics 
of the material that must be considered are the tensile strength and the volume capacity 
(bed volume). Both of these must be optimized to yield a sample pad which is strong 
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enough to undergo handling and reagent loading and has a large enough bed volume to be 
able to hold the entire sample. The bed volume, defined as the volume of air in the pores 
per unit surface area (e.g., mL/cm2), determines the total liquid volume that can be held by 
the material when the pores are completely saturated [14]. Tensile strength, defined as the 
force at which a membrane breaks, decreases proportionately with increasing pore size, 
creating an optimal range for high tensile strength and large pore size [16]. Typical tensile 
strengths for lateral flow membranes range from 1.75 to 8.8 Newtons/cm [16]. Most 
commonly, cellulose fiber filters and woven meshes are used in the sample pad. Cellulose 
fiber pads tend to have low tensile strength and higher bed volumes, while, conversely, 
woven meshes tend to have low bed volumes and high tensile strength. Due to the higher 
bed volume, cellulose pads are often ideal because of the ability to hold any pre-treatment 
reagents. However, the low tensile strength relative to the woven mesh means that the 
cellulose pads are brittle and must be handled delicately.   
 
1.4.2 Conjugate Pad 
After passing through the sample pad and undergoing any necessary pretreatment, 
the sample flows through the conjugate pad. Aptly named, the conjugate pad contains the 
conjugate antibody for the biomarker which the assay is designed to detect, e.g. the 
antibody and antigen, respectively. Similar to the sample pad pretreatment reagents, the 
conjugate is dried down onto the pad and re-solubilized by the sample. The conjugate pad 
must be able to store the conjugate in a stable state and then release it efficiently once the 
sample comes into contact with the pad. In order to properly dry the conjugate to the pad, 
the buffer solution must contain sugars for long-term stability and ease of re-solubilization 
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upon the arrival of the sample [15]. The sugar molecules in the buffer create a layer around 
the conjugate that works to stabilize the physical structure for long-term storage [16]. These 
sugar molecules dissolve in the sample fluid, allowing the conjugate to release and be 
carried by the fluid stream, binding to the specific antibody [16]. The conjugate is tagged 
with a label that will later be used to indicate capture and indicate the presence of the 
analyte of interest. If the conjugate and label complex is not appropriately dispensed or 
dried down onto the conjugate pad, then the release of the conjugate will be affected, which 
could have an adverse effect on the results of the test and the overall sensitivity of the assay 
[17]. Labels used in lateral flow assays include gold nanoparticles, colored latex beads, 
magnetic particles, carbon nanoparticles, selenium nanoparticles, silver nanoparticles, 
quantum dots, organic fluorophores, textile dyes, enzymes, liposomes and others [17]. The 
choice in label depends on the quantity of steps and the final detection method desired. 
Some of the labels listed above generate a direct signal, e.g. the gold nanoparticles showing 
as a deep red, while others require an additional step, e.g. the enzymes which fluoresce 
when an appropriate reaction substrate is added. Additionally, some labels are limited in 
only being qualitative in nature – only returning a yes/no response to the presence of the 
analyte.  
 The choice of material for the conjugate pad is important due to the fact that if the 
conjugate is not correctly bound to the pad and released with the sample, then the test will 
not be accurate. Since the conjugate pad needs to be able to hold a large volume, porous, 
non-woven filters are commonly used, which are fibers of cellulose, glass, or plastic (such 
as polyester, polypropylene, or polyethylene) compressed into thin pads [14]. These filters 
have large bed volumes and will hold the full volume of reagent require to suspend the 
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labeled detection antibodies. Further, the pad must be able to consistently release the 
detection antibody when the sample fluid flows over it and the analyte binds. The release 
occurs when the sample solubilizes the antibody, carrying it down the remainder of the 
assay [13]. Additionally, neither the detection antibody nor the analyte should bind to the 
conjugate pad, meaning that the pad material, either intrinsically or after pre-treatment, 
must exhibit low non-specific binding.  
 
1.4.3 Membrane 
When the fluid has flown across the conjugate pad, it reaches the membrane. The 
membrane is the bottom later of the lateral flow assay and it contains the detection region 
of the test, namely, pre-bound capture antibodies. The purpose of this analytical region is 
to bind the analyte and detection antibody complex from the conjugate pad onto the 
membrane to allow for quantitative or qualitative test results. Similar to the conjugate pad, 
the membrane also needs to be able to store capture antibodies for the duration of the test’s 
shelf life [14]. Also, when the test is running, the membrane must facilitate consistent 
sample capillary flow, allowing the analyte to bind the capture antibody while the other 
excess buffers, labels, and reactants pass without binding [14]. Typically, the analytic 
region has two lines: the test line and the control line. Antibodies that are specific to the 
analyte of interest are immobilized on the membrane test line in a strip and will capture the 
analyte and labeled detection antibody complex when it flows through the line. If the 
analyte is present in the sample, it will bind on the antibodies on the test line and the labeled 
conjugate antibody will visually signify binding with color, indicating a positive result 
[13]. The control line is used to validate that a sufficient concentration of detection 
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antibody was introduced to the assay and that the lateral flow assay functioned correctly. 
It is created by immobilizing, “species-specific anti-immunoglobulin antibodies, specific 
for the antibody in the particulate conjugate” [14]. The test line should be designed with 
sufficient antibodies to bind enough of the conjugated complexes so that a visible signal 
will be returned, while some complexes flow past onto the control line and bind there, 
indicating that the test ran properly and the result from the test line is accurate. This reaction 
can be seen in the diagram below in Figure 4. 
 
Figure 4. Test and control line antibody loading and colorimetric display [14] 
The positive result shows both lines – the test worked, and the device detected the analyte. 
The negative result shows only the control line – the test worked, and the device did not 
detect the analyte. If the assay does not run correctly with enough detection antibodies, the 
assay will display a test line but no control line.  
 The analytical region of LFAs has historically been nitrocellulose, which is formed 
by nitrating cellulose through exposure to nitric acid, resulting in the polymeric structure 
seen below in Figure 5. 
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Figure 5. Chemical structure of nitrocellulose [18] 
Nitrocellulose is an ideal membrane because of its low cost, true capillary flow 
characteristics, high non-specific binding of biological macromolecules, relative ease of 
handling (with direct cast, or backed membranes), and, with specific material treatments 
and manufacturing processes, varying wicking rates and surfactant contents [14]. 
Nitrocellulose sheets are typically sold by pore size, ranging from 0.05 to 12 μm; however, 
since the pores are not evenly distributed throughout the material, it is more accurate to 
choose the nitrocellulose using the capillary flow time (seconds/cm) which defined as the 
time taken for the sample to completely fill the length of membrane [19]. A larger pore size 
correlates with a lower capillary flow time, and a smaller pore size correlates with a higher 
capillary flow time [15]. The sensitivity of the assay increases as the flow time decreases 
because the sample is able to incubate for a long time with the detection molecules.  
The other important component of the nitrocellulose is its ability to bind the 
antibody protein. As seen in Figure 5, nitrocellulose has strong dipoles on the nitrate ester 
(positively charged nitrogen and negatively charged oxygens) which allows it to 
electrostatically bind to the antibody and its polar peptide bonds, directly adsorbing the 
antibody to the surface of the nitrocellulose [16h]. Other methods include covalent 
attachment of thiolated affinity protein to GMA-modified nitrocellulose, anchoring of 
biotinylated affinity protein to streptavidin, and genetic fusion of affinity protein to custom 
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nitrocellulose-binding anchor protein which are useful in increasing the binding ability of 
the nitrocellulose, particularly when the capture agent is not an antibody [20]. 
 
1.4.4 The Absorbent Pad 
The final component of the lateral flow assay is the absorbent (wicking) pad, seen 
at the far end of the LFA in Figure 3. The function of this pad is to create void space for 
the sample to flow past the test and control lines, allowing sufficient accumulation while 
the assay reaction occurs. [14]. In general, the total volume of sample that the assay can 
handle is controlled by the bed volume of the absorbent pad, therefore, a pad with a bed 
volume large enough to accommodate both the sample and reagent buffer volume [15]. 
The absorbent pad is typically cellulose. The same considerations that were made for the 
sample pad apply for the absorbent pad. 
 
1.4.5 Device Housing 
The final component of the lateral flow assay is the housing, which encases the 
device, holds the various pads together, and applies regions of pressure at precise locations 
to ensure connectivity and aid in fluid routing. The housing should be designed to expose 
the sample pad and allow for viewing of the analytical region where the test and control 
lines will appear after the test has completed [14]. Depending on the design, adhesive may 
be used in addition to the housing to hold the assay layers together. The housing design 
needs to be carefully considered because the connectivity of the assay material layers is 
reliant on the pressure from the housing and any internal bars or pins which work to hold 
the materials in contact as well [14]. Due to this, it is important to consider the thicknesses 
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of each of the pads because any variation will create a variation in the pressure from the 
housing – thin layers resulting in little to no contact and thick layers resulting in over 
compression [19].  
 
 Paper-Based Microfluidic Assays 
A relatively new technology in the assay space is the paper-based microfluidic 
assay (referred to as μPADS) which uses the chemical reactions seen in lateral flow assays 
and adapts them for use on a paper-based system. Paper is a cellulose fiber web with a high 
surface area, which is abundant, inexpensive, and compatible with biological samples, 
making it an ideal platform for the application of assays [21]. In general, these microfluidic 
devices are made of patterned paper on which a small volume of fluid will move by 
capillary action and ultimately yield results in a manner similar to the LFA, at a lower cost, 
while being less technologically complex, and more environmentally friendly [22].  
Typically, the paper is a cellulose material for fluid routing and a nitrocellulose 
material for the detection region, similar to those used in LFAs [21]. These are ideal 
because they are affordable, naturally hydrophilic, and allow for rapid liquid movement 
across the surface and through their bulk. The paper is patterned with hydrophobic areas to 
create barriers that direct the fluid movement both in plane and out of plane (3D) directions, 
depending on the assay’s intended use. The hydrophobic barrier must fill the entire 
thickness of the paper in order to create a barrier for the channel from which the fluid 
cannot escape [23]. Various approaches, including cutting, photolithography, plotting, 
inkjet etching, plasma etching, wax printing, etc., are utilized to create the fluid flow 
channels, as seen in the cross section in Figure 6 below [24].  
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Figure 6. Hydrophilic channel created by hydrophobic barrier [22] 
1.5.1 Photolithography 
The first method developed to create these channels was photolithography, which uses 
UV light to develop the fluid flow design onto the paper. One example of this process was 
developed by Martinez, et al. in 2008 in order to rapidly produce assays from novel fluid 
flow designs, aptly named FLASH (Fast Lithographic Activation of Sheets) [25]. The steps 
in the creation are outlined below:  
(i) Impregnate paper with photoresist and allow it to dry. 
(ii) Cover one face of the photoresist-impregnated paper with an adhesive 
transparency film and the other face with black construction paper. 
(iii) Print a pattern onto the transparency film using an ink jet printer, a 
photocopying machine, or a pen. 
(iv) Expose the paper to UV light. 
(v) Bake the paper to polymerize the photoresist. 
(vi) Remove unpolymerized resist by washing the paper with acetone and isopropyl 
rubbing alcohol [25]. 
This novel method was a breakthrough for paper-based microfluidics because it allowed 
for rapid prototyping at an inexpensive cost with relatively simple materials and processes 
at an approximate cost of $26.53/m2. While simple, the method is capable of creating 
 17 
hydrophilic channels as small as 100 μm wide, and hydrophobic barriers to direct the flow 
as small as 200 μm wide [24]. The fourth and fifth step could be replaced by sun exposure 
at the cost of pattern accuracy in order to further simplify and cheapen the materials 
required for the process. Photolithography started a movement to create diagnostic devices 
that are accessible and cheap, when compared to traditional LFAs.  
 
1.5.2 Wax Printing 
 Wax printing of μPADs arose as an alternative to other more expensive options in 
2009 from the groups of Carrilho et al. (2009) and Lu et al (2010) [26][27]. This method 
is considerably less expensive than photolithography at $1/m2 and requires fewer materials 
and a less complex process, making it the most widely accessible method for paper-based 
assay creation [28]. There are currently three main methods for hydrophobic barrier 
creation, including: (i) painting with a wax pen, (ii) printing with a normal inkjet printer, 
followed by tracing by painting with a wax pen (iii) direct printing by a wax printer [28]. 
The steps for the direct printing method are very simple: first, the barrier design is printed 
onto the paper using a wax printer and then the wax is melted through the paper using a 
hot plate, as outlined in Figure 7 below [22]. 
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Figure 7. The process of wax printing to allow for fluid flow channels [22] 
Typically, this process takes 5-10 minutes from start to completion and is 
environmentally friendly since the wax and paper can be disposed of via burning. The 
downfall of wax printing is that during the melting process, the wax melts both downward 
through the bulk of the paper and laterally across the surface, infringing on the hydrophilic 
channels [21]. By studying the relationship between applied heat and wax spreading, 
Carrihlo et al. were able to produce minimum barrier and channel widths of 850 and 560 
μm, and when applied to nitrocellulose, Lu et al. (2010) were able to create channels as 
thin as 300 μm and 60 μm barriers [27].  
 
1.5.3 Creation of Assay  
 In order for the device to be used diagnostically, the hydrophilic path must include 
a detection zone in which a chemical reaction can occur. This includes an acid–alkali 
reaction, a precipitation reaction, a reduction-oxidation reaction, or an enzymatic reaction 
between the target analyte and any immobilized reagents [28]. These reactions produce a 
signal which can be detected by colorimetric, electrochemical, fluorescent, or a variety of 
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other methods, depending on the application of the device [28]. For example, the 
photolithographic device created by Martinez et al. was used to test for glucose and proteins 
using well known colorimetric assays commonly used in urine analysis [21]. The glucose 
test reacted the sample with potassium iodine mixed with horseradish peroxidase and 
glucose oxidase, which led to the detection zone changing color from clear to brown [23]. 
Protein concentration was analyzed using citrate buffer with tetrabromophenol blue and 
colorimetric change from yellow to blue. The different chemicals and enzymes were 
spotted at the last step of the device fabrication and left to dry in the detection zones, as 
seen in Figure 8 below [21]. 
 
Figure 8. Progression of analytical testing of the paper microfluidic device [23] 
Similar to an ELISA, μPADS can detect a specific antigen using bound and labeled 
antibodies and then display a signal using an enzymatic (colorimetric) reaction which is 
proportional to the quantity of analyte. In a 2012 publication, Wang et al. demonstrated the 
ability to conduct a complete ELISA on a wax screen-printed chromatography (cellulose) 
paper using chitosan-modified paper to covalently immobilize antibody and detect specific 
antigens [29]. However, this device requires a holder specifically created to mount the 
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assay, incubate it with the sample and antibodies, and read out the colorimetric results, 
making it impractical for use outside of the lab, which was the original intention of the 
paper-based assay [29]. Proving that the chemistries of ELISAs can be implemented on a 
paper-based device is important to the continuation of this field of diagnostics.  
 
1.5.4 3D Microfluidic Devices 
 The examples previously shown of μPADS were all single-layer, lateral flow 
systems. However, the field has progressed to include three dimensional devices which 
utilize layers of paper stacked upon each other in order to route the liquid in the vertical 
and horizontal planes. The individual papers are patterned in a way that allows the fluid to 
flow through the intended path through hydrophilic areas overlapping between the layers 
[22]. The design must allow for the alignment of hydrophilic areas so that the fluid may 
continue to flow. Often, these layers are held together using double-sided adhesive tape 
that are also cut in corresponding patterns to allow for the paper layer conductivity. Since 
the tape creates a small, but significant, distance between the adjacent layers, a paste made 
out of cellulose powder and water can be used to fill in the holes cut in the tape to further 
aid in connectivity [25]. Another method used to create the three-dimensional movement 
is by using “origami” folding patterns which cause the overlap of paper layers and thereby 
creating the continuous fluid networks. Alternatively, the layers are held together using 
specifically designed plastic housing which includes ports which allow for sample input 
and result read out. 
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1.5.5 ELISA-Like Assay 
Building off of the idea of µPADs with lateral flow assay functionality provides the 
next logical step in the device development: incorporation of ELISA-like functionality onto 
a paper-based system (P-ELISA) in order to provide the sensitivity and specificity of an 
ELISA in a cheap, easy to use, and portable system. The main benefit to this inclusion is 
the fact that ELISAs are run using antibodies which are conjugated to enzymes which cause 
fluorescence when presented with a substrate [30]. The initial and simplest designs of a P-
ELISA involved the creation of circular portions of cellulose paper made using photoresist, 
as described above, following the FLASH method designed by Martinez, et al (2008) 
[25][30].  
 
Figure 9. Paper-Based ELISA Format with Photoresist on Paper [30] 
Here, the reagents are deposited by hand onto each zone, one at a time, with wash steps 
between, in order to fully mimic the way that an ELISA would be completed using a 96-
well plate. These early formats were able to get limits of detection (LOD) significantly 
lower than that of a standard ELISA and receive results approximately four times faster 
than an ELISA, all while using a smaller volume of reagents on a cheaper and easier to 
fabricate platform [30][31]. A downfall of this specific design is that all of the reagents 
need to be manually placed on to the paper by the end-user, as opposed to coming 
 22 
incorporated with the device, as in traditional LFAs, leading to increased likelihood of error 
when running the assay. Furthermore, the large paper does not have a housing nor is it 
portable, making it difficult to bring to the end user. This design was improved on further 
with the creation of sliding P-ELISAs, where a separate paper card was designed and 
assembled to slide laterally in relation to the test zone [32]. In this iteration, the antibodies 
and other reagents were stored on the card and resolubilized using water or buffer solutions 
to allow the sample to mix and deliver a result, as in Figure 10 below.  
 
Figure 10. Sliding Format for a P-ELISA Showing the Layers and Reagents [32] 
In this format, the sample is added to the first circle, as shown above, and then the 
subsequent steps are water which is used to resolubilize the proteins bound to the cellulose 
layers above the sample strip. Finally, the result is read when the strip is pulled the entire 
way out of the device. This test, while allowing for on board reagent incorporation, only 
allows for one sample to be tested for one protein at a time. A multiplex assay would allow 
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for several biomarkers to be tested for in one sample in order to gain a more useful 
diagnosis for complex pathologies. Also, since the layers are not seen to the end user, it is 
hard to line up the test region properly using only the guidelines on the sliding strip [32]. 
This thesis seeks to improve on the current P-ELISAs by allowing for on board reagents 
which can specifically and sensitively detect the presence of a biomarker in a multiplex 
fashion. 
 
 On Board Reagent Incorporation 
The further development of the paper-based microfluidic assay to include the 
reagents onboard the device will allow for minimal sample preparation and reduce user 
error when in a clinical or research setting. Creating a system for on-board reagents thus 
improves the robustness, affordability and ease-of-use of the device while minimizing the 
amount of external interaction required, including test equipment [33]. Because the paper 
platform is porous, it has the ability to store liquids, such as assay reagents, that would 
typically be separate and added manually to the assay [34]. These reagents will resolubilize 
once the sample is added to the device and flows past the dried down reagent. The process 
for adding the reagents is straightforward; the reagent is either spotted on the paper or the 
paper itself is fully submerged in the reagent. Then, the paper is left to dry and incorporated 
into the device and left until the device is used, similar in concept to the lateral flow assay. 
The main challenges faced with reagents in paper-based devices is the stability of the 
reagent, which relies on careful temperature control, and the controlled release of the 
reagents so that the sample has sufficient time to interact and react [28][33]. After loading 
the reagent onto the pad, storage at colder temperatures is desired as it maintains the activity 
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of the antibodies, however, signal has been seen to only minimally decrease when stored 
at room temperature (20°C) and hot temperatures (45°C), as seen in Figure 11 below. 
 
Figure 11. Chart showing the effect of long-term dry storage of the conjugate on assay 
performance [Stevens] 
The conjugate antibody was preserved with a sugar addition at varying percentages, 
as shown above, in order to determine if there was an effect on storage temperature and 
conditions on the resulting signal [35]. When comparing the temperatures at 5%/5%, there 
is a clear, but small, decrease when stored at 45°C for 60 days, however, the 4°C and 20°C 
storage temperatures did not show much of a decay in signal. This means that the device 
could be stored at any temperature, most preferably around 20°C, and maintain its 
functionality [35]. Dried reagents would be resolubilized with buffer, such as PBS, for 
delivery to the sample. The incorporation of these reagents on board work to minimize user 
steps, remove the need for a cold chain, and create nearly automated devices [33]. 
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 Characteristics of Fluid Flow in Paper Microfluidics 
 Paper-based microfluidic devices can entirely and autonomously run on capillary 
action, which occurs as the result of the intermolecular attraction within the liquid and solid 
materials [34]. The liquid is able to flow in narrow spaces without external input of energy 
due to the imbalance of adhesive forces between the liquid and the material and the 
cohesive forces within the liquid itself [36]. The liquid begins to move when the adhesive 
forces are greater than the cohesive forces. Typically, capillary flow is understood as the 
flow of liquid through a small cylinder, which can be determined using Poiseuille’s law, 
equation 1 below: 
𝑄 =	∆𝑃𝜋𝑟(8𝜂𝑙  
Where the flow rate, Q, is determined by the pressure gradient in the tube, P, the radius of 
the rube, r, the length of the tube, l, and the viscosity of the fluid, 𝜂. This relationship only 
applies to the laminar flow of an incompressible liquid, however, when integrated with 
respect to time and inclusive of the total driving pressure with the capillary open at both 
ends, the resulting equation is descriptive of the flow of liquids under its own capillary 
pressure [36]:  𝐿. = /01(2 𝑐𝑜𝑠𝜃 
where L is the distance moved by the fluid front, t is time, D is the average pore diameter, 
γ is the effective surface tension, cosθ is the contact angle dependence, and μ is viscosity. 
This equation is known as the Lucas-Washburn equation and can be extrapolated to fluid 
flow through porous media by taking the penetration of the pores by a liquid as equal to 
the penetration of n cylindrical capillary tubes of varying radii [36]. Per the understanding 
of capillary flow, the force due to the surface tension resulting from the adhesive force 
(1) 
(2) 
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between the liquid and the pores pulls the fluid further into the paper [37]. With 
simplification, as shown above, Washburn-like flow is characterized by L ~ √𝑡, which 
implies that the fluid front velocity decreases with time. As the surface tension is pulling 
the water into the paper’s pores, the viscous resistance slows the fluid front down, resulting 
a decrease in flow velocity of the fluid front as it enters the porous media [37]. 
 
1.7.1 Wicking 
When specifically referring to capillary flow within a porous media, wicking is the 
action of spontaneous absorption that occurs [38]. While the Washburn equation is often 
sufficient enough to estimate this action, it has distinct shortcomings with ignoring the idea 
of a preferred pathway of flow through a medium with non-homogenous pores [39]. 
Namely, pores with a relatively small diameter will fill faster than those with larger 
diameters, thereby advancing the fluid front up the medium through adjacent small pores 
at a faster rate than the large pores [39]. Additionally, the Washburn equation is limited to 
one dimensional wicking due to the original approximation using capillary tubes [38]. In 
order to adjust for these shortcomings, Darcy’s Law can be used:  
𝑄 = −𝜅𝐴𝜇𝐿 𝛥𝑃, 
 
where Q is the volumetric flow rate, κ is the permeability of the paper to the fluid, μ is the 
viscosity of the fluid, A is the area of the channel perpendicular to flow, and ΔP is the 
pressure difference along the direction of flow over the length L [37]. Darcy’s law applies 
to fully-wetted flow, where the fluid front has reached the wicking pad and the velocity of 
the fluid flow is approximately steady [37]. Pressure can be estimated using only the 
(3) 
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definition of capillary pressure, below, because the atmospheric pressure difference in the 
device is equal to zero. 
𝑝@ = 	2𝛾𝑐𝑜𝑠𝜃𝑅DEFG  
Where Eq. 4 can then be substituted in to Eq. 3 for the volumetric flow rate in a series of 
capillaries taken as equivalent to a porous media. Dividing by area results in Eq. 5 below, 
the velocity of fluid flow through cellulose paper with consideration of wicking and 
capillary flow. 
𝑣 = − 𝜅𝜇𝐿 2𝛾𝑐𝑜𝑠𝜃𝑅DEFG  
The continued development of equations to model fluid flow characteristics in porous 
media is important to understanding the variables that can be changed for components of 
the paper-based microfluidic devices in order to control the flow rates and achieve optimal 
results in both lateral and 3D microfluidic devices.  
 
 The Diagnosis of Stroke 
A stroke occurs when there is an interruption to the flow of blood in the brain, due 
to either a physical blockage or a broken blood vessel. Strokes are divided into two 
categories: hemorrhagic and ischemic. Hemorrhagic strokes are due to a blood vessel 
bursting due to pressure or stresses at the vessel wall, allowing blood to leak into the brain, 
creating swelling and pressure which, in turn, damages the neural cells and tissue [40]. 
Ischemic strokes occur when a blockage is formed in or travels to a cerebral blood vessel 
and the flow of blood is stopped to that area of the brain. The blockage can be caused in 
several ways, including the atherosclerotic buildup of fat and plaque. Further, they can be 
(4) 
(5) 
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characterized as a thrombotic stroke, where a blood clot formed at the stroke site, or as an 
embolic stroke, where a blood clot traveled through the vasculature from elsewhere in the 
body until it was stopped by a small enough vessel [41]. Regardless of the cause, a lack of 
blood to the brain tissue leads to hypoxia and irreversible cell death.  
Hemorrhagic strokes are treated in a variety of different ways, all for the main goal 
of stopping the brain bleed. Primarily, doctors will attempt to lower the patient’s blood 
pressure using medication or a ventilator. Later, a surgical clip may be placed at the base 
of the brain aneurysm to remove blood flow and stop the bleeding, an invasive procedure 
which requires a portion of the skull to be removed [42]. Ischemic strokes are often treated 
using tissue plasminogen activator (tPA) which is a protease found on endothelial cells that 
breaks down clots [43]. Due to the extreme nature of stroke and relatively quick damage 
to the brain, the earlier a stroke is caught and diagnosed, the better the patient outcome. 
Correct diagnosis is vital because the anti-coagulation medication given to ischemic stroke 
patients would be deadly to hemorrhagic stroke patients as the ruptured vessel would be 
unable to clot and mitigate blood flow. 
In emergency rooms today, a CT scan is the standard for assessing the presence and 
extent of neurological trauma. This test can show areas of abnormalities in the brain and 
can help to determine if these areas are caused by ischemic stroke, hemorrhagic stroke, or 
a different kind of a problem [44]. Unfortunately, without contrast solution, CT scans miss 
ischemic strokes, which account for ~80% of strokes [45]. Therefore, a stroke will not be 
diagnosed efficiently, which would increase the risk of long-term complications and even 
death.  
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1.8.1 Biomarkers 
During and after a stroke, there are detectable macromolecular signals, biomarkers, 
in the blood stream that can be used to diagnose the disease [4]. These molecules must be 
able to be detected and correlate to ischemic stroke in a repeatable, reliable, and accurate 
manner. Currently, several protein biomarkers are considered indicative of ischemic stroke, 
including C-reactive protein, lipoprotein-associated phospholipase A2, and urinary 
albumin excretion [46]. Other biomarkers have been well studied in stroke including 
natriuretic peptides, glial fibrillary acidic protein (GFAP), S100b, neuron specific enolase 
(NSE), myelin basic protein (MBP), interleukin-6, matrix metalloproteinase (MMP)-9, D-
dimer, and fibrinogen [46]. The problem with using biomarkers to detect and diagnose 
stroke is that each stroke is heterogeneous and has large variability in location, size, and 
cause, therefore some assays may not include the specific biomarker that a patient suffering 
from stroke is producing in their bloodstream. Therefore, researchers are seeking out a 
something akin to a “mosaic” of biomarkers, or a protein panel, which together lead to a 
better and more accurate diagnosis than they would separately. In order for a complete and 
highly accurate diagnosis, one device would need to be able to indicate the presence of a 
variety of biomarkers that have all been contraindicated to ischemic stroke. In a 
comprehensive study of published ischemic stroke biomarker panels, Jickling and Sharp 
(2015) compiled the results of several studies on ischemic stroke detection, specifically in 
regard to the proteins used and the reported sensitivity and specificity [46]. A brief 
selection of that information can be found in Table I below. 
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Table I. Biomarker Panels for the Diagnosis of Ischemic Stroke [46] 
Panel Comparison Assay Platform 
Sample 
Size 
Markers 
in Panel 
Sensitivity/ 
Specificity 
Five 
protein 
panel 
Ischemic + 
hemorrhagic 
stroke vs 
control 
ELISA 437 
BNGF, 
MCP-1, 
MMP-9, 
S100B, 
vWF 
92%/93% 
Four 
protein 
panel 
Ischemic + 
hemorrhagic 
stroke vs 
control 
ELISA 1,289 
BNP, D-
dimer, 
MMP-9, 
S100B 
86%/37% 
Four 
protein 
panel 
Ischemic 
stroke vs 
control 
ELISA 222 
MMP-9, 
S100B, 
VCAM1, 
vWF 
90%/90% 
 
Of note in this table is the fact that the panels were comprised of a set of either four or five 
proteins which together gave high values for sensitivity and specificity, in the case of the 
first and last panel, yet gave low specificity in the middle panel. This indicates that the 
specific protein makeup of the panel has a large influence on the success of the diagnosis 
and changing a few biomarkers can have a marked result in the test specificity.  
Furthermore, this subset of data also only looked at ischemic and ischemic + 
hemorrhagic stroke populations versus control populations, rather than ischemic stroke 
versus hemorrhagic stroke. It is simpler to differentiate a stroke patient from a healthy 
patient because there would be a greater number of biomarkers which would be 
significantly expressed differently in the stroke patient versus the control. When comparing 
ischemic and hemorrhagic stroke, the protein differences between the two pathologies 
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become more indiscernible. Stroke biomarkers, in general, appear as the result of brain 
tissue damage, inflammation, endothelium damage, and coagulation/thrombosis that is 
occurring with either type of stroke, hemorrhagic or ischemic [46]. This is further muddled 
by the fact that stroke biomarkers are also elevated in response to other conditions, such as 
traumatic brain injury, severe myocardial infarction, and brain infection [47]. Additionally, 
adding to the challenge of using biomarkers for stroke, the blood-brain barrier slows the 
diffusion of proteins into the blood stream, making it difficult to obtain a sample of blood 
with the sought-after biomarkers.  
S100 beta (S100B, or S100β) is a calcium-binding protein expressed by the human 
body in response to central nervous system injury [48]. This protein has been associated 
with ischemic stroke in several published articles which analyzed both the physiological 
response to stroke as well as the accurate diagnosis of the condition [46] [48] [49]. For the 
scope of this thesis, S100B will be acting as the target antigen in the patient sample in order 
to diagnose an ischemic stroke. 
 
 A Global Approach to Diagnostic Medicine 
As the understanding of the cellular mechanisms within the human body advances, 
so does biomedical technology. This leads to new methodologies for detection and 
diagnosis of diseases, infections, and other pathologies which were previously unknown. 
These detection methods are becoming more sensitive and are able to detect a larger variety 
of molecules with higher accuracy. Developing these advanced techniques across all fields 
of medicine and diagnostics comes with years of research and design which is often very 
costly. These technologies are often complex and expensive to manufacture and require the 
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user to have a specific, trained skillset in order to operate the device. Therefore, gains have 
been made in the point-of-care (POC) space, with the design goals of cheap and disposable 
devices that can be used in almost any space with small amounts of experience. These POC 
devices allow a patient to get accurate results in a reasonable time frame without the need 
for a visit to a large clinic or hospital, which may be unattainable in some areas. Further, 
these devices are portable and could be taken into remote areas where people would benefit 
from access to diagnostic medicine for pathologies such as malaria and HIV. Therefore, 
the creation of paper-based µPADs, as described above, are a cheap, easy, and fast 
diagnostic method will allow for the widespread detection and characterization of diseases 
which can be detected using specific biomarkers.  Often times, these devices are forced to 
sacrifice sensitivity in order to work in the environments seen in developing countries due 
to the lack of equipment and efforts to make the devices low cost [50]. Dry-form reagent 
storage on a paper-based microfluidic system could lead to the future of POC diagnostics, 
allowing sensitive and specific diagnoses for people across the globe.  
With this in mind, the World Health Organization (WHO) via the Sexually 
Transmitted Diseases Diagnostics Initiative (SDI) has created a series of guidelines for the 
quality of a diagnostic test that would be used in developing countries [51]. The ASSURED 
criteria are as follows: Affordable, Sensitive, Specific, User-friendly, Rapid and robust, 
Equipment-free and Deliverable to end-users. These guidelines are meant to be a 
benchmark to determine if the test meets the needs of the community it would be servicing. 
It is important that throughout this thesis project, the ASSURED guidelines are considered 
so that an eventual implementation into developing countries could be feasible. 
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 Dissemination of Previous Work  
The Cal Poly Biofluidics lab has been doing research on µPADS since 2012 under 
the guidance of Dr. David Clague. Clayton (2012) and Ward (2012) designed and 
characterized several formats of paper-based microfluidic platforms using nitrocellulose 
[52] [53]. Clayton (2012) compared anti-VEGF antibodies and aptamers on paper 
microfluidic-based platforms, centered around creating a device to detect the VEGF protein 
using antibodies and aptamers, or segments of DNA specifically designed to target a 
protein, similar to a paratope on an antibody. Notable results included the determination of 
an optimal channel width of 1.6 mm, the confirmation of the homogeneity of fluid flow 
through nitrocellulose paper and, conversely, the heterogenicity of fluid flow through 
cellulose paper [52]. Similarly, Ward (2012) developed a nitrocellulose paper-based 
microfluidic platform with surface functionalization using anti – IgE aptamers. This 
research determined a channel width of 1.6 mm in order to create optimal fluid flow times 
for the lateral flow assay that was used to detect IgE using aptamers [53]. Tageson (2013) 
brought the technology into 3D applications, routing fluid in the lateral and vertical 
directions to allow for a series of reactions for binding the IgE analyte to the aptamer for 
detection using fluorescence [54]. Young (2016) created a multiplex 3D assay device using 
a similar method in order to detect glucose presence in a sample via a 3-D multiplex paper-
microfluidic platform, which did not deal with an antibody/antigen immunological reaction 
but did further validate the 3D functionality of wax-printed, paper-based assays [55]. Most 
recently, Holler (2016) continued the work of Tageson (2013) and was able to design a 
rotating paper-based µPAD using wax printing which had the theoretical ability to carry 
out a functional ELISA-like assay [56]. However, in the work, they were unable to fully 
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demonstrate a device that used on board reagents, i.e. the inclusion of the detection 
antibody on the conjugate pad [56].  
In separate, but related, work, Daugherty (2015) created code that could determine 
absorbance values of an assay which used gold-labeled nanoparticles to quantify a signal 
[57]. Van Huynh (2016) further created MATLAB code that quantifies color intensity of 
an HRP-bound antibody on cellulose with a smart phone image [58]. Both Daugherty and 
Van Huynh were able to obtain statistically valid results of color intensity using their 
respective code run on a cell phone image of a completed assay [57] [58].  
Moving forward with my own thesis, I will build off of the work done by Alicia 
Holler in the creation of a 3D paper-based, microfluidic device that is built to enable an 
ELISA-like assay for the detection and diagnosis of ischemic stroke.  
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2. MATERIALS AND METHODS 
The process of the creation and associated testing of the 3D microfluidic chip 
(μPAD) and housing will be explained in this section. This device was built upon previous 
work completed by Holler (2016) with the initial attempt to incorporate an ELISA-like 
assay onto a paper microfluidic chip by successfully characterizing fluid flow through a 
3D chip design. However, that work was unable to achieve reagent loading to accurately 
test for a specific antigen [56]. With the design in mind, a series of experiments were 
conducted to initially determine the fluid flow characteristics of the device and to ensure 
the connectivity between layers. Then, the device was redesigned to incorporate the desired 
features that would be required for an ELISA before proceeding with the biological 
implementation of an ELISA-like test onto the paper platform. Then, the onboard reagents 
were incorporated into the device to specifically test for the presence of the S100B protein. 
These reagents were optimized for specificity and sensitivity of the assay as well as 
consideration of cost, ease of manufacturing, and overall ease of use for the end consumer. 
 
 3D Paper Microfluidic Chip Fabrication 
Various iterations of designs were created in order to determine the optimal layout 
and sizing for each layer of the device based on previous work, published literature, and 
further development from optimization tests. AutoCAD™ was used to design and develop 
the layers for the μPAD. In general, each design was fabricated, as described below, based 
on a standard method employed in several past theses. 
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2.1.1 Wax Printing 
The μPADs were created using the wax printing technique similar to that described 
in the introduction. By designing the layers on AutoCAD™ and setting the wax-printed 
areas to a black hatch pattern, the fluid flow pathway could be created, eventually allowing 
for reactivity and detection. Whatman™ 1 mm thick, 20 x 20 cm chromatography Paper 
(CAT No. 3001-861) was purchased from GE Healthcare Life Sciences and was used as 
the cellulose material for the fluid routing layers of the device. Whatman™ 3 mm thick, 
20 x 20 cm chromatography Paper (CAT No. 3030-861) was purchased from GE 
Healthcare Life Sciences and was used as the cellulose material for the absorbent pad. 
Glass fiber conjugate pad (GFCP103000) was purchased from EMD Millipore and was 
used as a conjugate pad. Unbacked HiFlow Plus nitrocellulose (HFB135UB) was 
purchased from EMD Millipore for use as the detection layer.  
The designs were printed from AutoCAD to a Xerox® Phaser® 8560 printer with 
Xerox® black solid ink. Once the layers were printed, they were individually placed on a 
Clarkson IKA® C-MAG HP 10 digital ceramic hot plate at 120°C for two minutes until 
the wax was melted through the cellulose and could be seen on the bottom side. The even 
heating was aided with a pair of metal tweezers used to press down on the paper to ensure 
complete melting. After melting, each layer was cut out appropriately using a McGill 
Punchline 3/16” round hole punch. The detection layer was attached to the top layer using 
3M™ Double Coated Tape 415. At this point, the device was assembled, layer by layer, to 
create the final μPAD.  
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2.1.2 Housing Fabrication 
As with any paper-based device, a housing is required to keep the layers oriented 
correctly and to apply even pressure throughout to ensure connectivity. The housing must 
also be able to deliver the sample to the sample pad and also display the results of the test, 
as well as accommodate for end-user functionality and ease of use. AutoCAD was used to 
design the housing components. The housing design was then laser cut into acrylic sheets 
of varying thicknesses using a Universal Laser System PLS6.150D platform. The pieces 
were held together using screws, as described in a later section.  
 
 Analysis of Previous Work 
Initially, all tests were performed on cellulose paper to establish fluid connectivity 
on a cheap material with controlled characteristics. The previous design created by Holler 
(2016) was opened on AutoCAD and printed at a 1:1 scale. The design can be seen in 
Figure 12 below. Dimensions for this design were based on previous work by Tageson 
(2013) and Ward (2012) [53] [54]. A dimensioned drawing can be found in the Appendix. 
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Figure 12. Previous final chip design from Holler (2016) [56] 
This design incorporated five layers in total. Layer two was comprised of two 
individual pieces – the conjugate pad and the detection pad. These layers would be glued 
together and then, as a unit, glued to the underside of the sample pad, layer one. Layers 
three and four would be used as fluid-routing and layer five served as the absorbent pad to 
cause the wicking action through the device. The principle of this design is the pin-wheel 
action achieved by fixing all of the layers together in the center with a screw and allowing 
layer one to rotate independently of the exterior screws with arched slots along the exterior 
that would be cut out after printing. This rotation would open up new channel pathways 
that could be used for further reagent incorporation and/or wash steps. In this design, there 
is one main channel and one additional channel used after rotating the top layer.  
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The previous work also included production of a housing unit, seen below in Figure 
13, which was also analyzed. Dimensioned drawings can be found in the Appendix. 
 
Figure 13. Previous final housing from Holler (2016). A) AutoCAD design, top of housing on 
left, bottom on right B) Assembled housing [56] 
This housing unit was designed in AutoCAD™ and laser cut as described in Section 
2.1.2. The layers were held together by inserting 0.266” diameter hex threaded inserts into 
the bottom layer using a benchtop press. The two layers were then held together with #8-
32 thread size, 3/8” length screws. 
In order to get an idea of the functionality of the device as described in the previous 
thesis, this design was printed as described above and inserted into the housing. Red dye 
was created by dropping one drop of red Kroger® Assorted Food Colors® into 15 mL of 
distilled water. This dye solution was used to determine if the fluid routing was functional, 
A 
B 
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specifically that the fluid would wick through all of the layers, appearing on the detection 
pad and the absorbent pad to indicate a complete test.  
 
 μPAD Design Evolution 
Based on the results from the previous thesis, the basic concepts behind the μPAD 
were kept in subsequent novel designs as a part of this thesis. This includes the wax printed 
circular layers which enable fluid routing in the lateral and vertical directions and can rotate 
to create connectivity to new channels to allow for wash steps and the addition of off board 
reagents. Dimensions for all drawings can be found in the Appendix. The first design 
iteration was based on the previous design, however it had the direction of flow inverted, 
i.e. the old design flowed sample from ports on the outside inward and the new design 
placed the sample ports on the inside and flowed fluid outward, as seen in Figure 14.  
 
Figure 14. Initial rotational outward flow design 
Layer one 
Layer two 
Layer three Layer four Layer five 
Layer two 
(nitrocellulose) 
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The long channels would be used to deliver the sample to the detection region. Then, the 
device would be rotated to align with the first new channel, allowing for a wash step to 
remove unbound antibody. Then, the test would be rotated again for an additional wash 
step. Finally, the test would be rotated a final time to allow for the addition of the substrate 
to indicate if there was a positive result. Similar to the rest of the layers, the smallest circle 
in layer two was designed to be made of cellulose, while the corresponding ring-shaped 
portion of layer two was to be printed on nitrocellulose. These two portions of layer two 
were designed to be taped together and then taped to the bottom of layer one to allow for 
rotation of the detection pads to the new channels.   
Additionally, a new format for the device was drafted, which used lateral motion 
as opposed to rotational motion, to expose new channels. This design can be seen below in 
Figure 15.  
 
Figure 15. Lateral motion pull strip design 
Layer one Layer two Layer two 
(nitrocellulose) 
Layer three Layer four Layer five 
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The basic concept behind this design was to take advantage of the sliding motion 
which could be achieved with a separate nitrocellulose strip, as in the device designed by 
Verma, et al. described in the Introduction [32]. To improve on their idea, the device would 
allow for a standard curve for quantification of the antigen based on a color change. Layer 
two would still be split into two – one portion cellulose and one portion nitrocellulose to 
allow for the creation of a detection pad. The nitrocellulose portion would then be pulled 
through the assay, exposing subsequent channels for additional wash steps. Because this 
design is linear rather than circular, it would be easier to add more sample channels and 
wash channels since it would simply require adding those portions to the bottom of the 
strip, rather than expanding the diameter of the circle of the rotational design to create more 
space. It was decided to move ahead with the rotational design over the lateral motion 
design due to the simpler housing and perceived ease of production for the rotating design. 
The outward flow design went through several series of design changes based on 
the evolving requirements for the ELISA functionality. First, the design was changed to 
include a fourth fluid channel and an area which could function as a control pad – similar 
to that in a lateral flow assay – which would show if the test ran correctly. In order to 
accommodate for this, the entire series of channels was expanded outward to create more 
space between each lane that could fit the maximum number of additional channels. This 
design can be seen in Figure 16.   
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Figure 16. Outward flow design with four channels and a control pad 
This design was created to maximize the quantity of additional reagents which could be 
added to the device – specifically increasing the potential amount of wash steps. As stated, 
a main reason why ELISAs are able to be sensitive is due to wash steps which remove 
excess proteins and reagents from the test area and only keep the ones which return a 
positive accurate result. The control pad is seen in layer one as the third ring of circles from 
the inside and correspondingly on layer two in the second ring of circles from the inside. It 
was further determined that the control pad would require its own wash steps as well in 
order to correspond appropriately to the color intensity of the detection pad and wash away 
unbound antibody for an optimal signal. Additionally, the number of additional channels 
was decreased to three because further research indicated that two wash steps and one wash 
with the substrate would be sufficient. This was added into the next design, seen in Figure 
17.  
Layer one 
Layer two 
Layer two 
(nitrocellulose) 
Layer three Layer four Layer five 
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Figure 17. Outward flow design with three detection pad channels and three control pad 
channels 
At this point, the overall design of the product was relatively stable. This led to the desire 
to determine overall functionality of the layered µPAD system as far as reagent flow is 
concerned. Before diving into the possibilities that could be explored within the rotational 
design, a lateral single channel test was created in order to validate fluid flow 
characteristics using red dye. The design for this test strip can be seen in Figure 18 below.  
Layer one 
Layer two 
Layer two 
(nitrocellulose) 
Layer three Layer four Layer five 
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Figure 18. Final design for one sample fluid flow validation test 
This design follows a similar layout to the rotational design, where the sample will be 
placed on the second from the left hole on layer one and proceed to flow through the rest 
of the device, down to the second layer, across layer three, up to the second layer detection 
pad, down again to the third layer, up to the second layer control pad, and down through 
the fluid routing fourth layer to the absorbent pad. The design also went through a variety 
of phases during testing, including varying the distance of the hydrophobic gap that forces 
the fluid upward to the detection and control pads.  
Later, a housing was built specifically for this test in order to improve connectivity 
between layers and more accurate mimic the intended final device functionality. The design 
was cut out of acrylic sheeting using a drill press. This housing can be seen in Figure 19 
and the full dimensions can be found in the Appendix. This housing allowed for easier and 
faster assembly of the layers. The further right and left circles in each layer were cut out in 
order to be fastened together with a screw at each end. 
Layer one Layer two 
Layer two 
(nitrocellulose) 
Layer three 
Layer four Layer five 
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Figure 19. AutoCAD design and acrylic production of the one sample test flow housing 
After the functional testing, the design was updated to include only a single print 
for the second layer, as opposed to two prints taped together as in previous designs. This 
began as a nitrocellulose “star” layer containing an area for the conjugate pad and a 
detection and control region which would be loaded with reagent and then taped to the 
underside of layer one, seen in Figure 20. This unit would then be rotated to expose the 
reagents to the sample and the subsequent wash steps. In the star layer – layer two – the 
inner circle would be punched out for alignment with the rest of the device. The next array 
of circles would be punched out as well, leaving an empty hole where the conjugate pad 
would be inserted. The conjugate pad would be correspondingly cut out of glass fiber pad 
using the same hole punch so that it would fit within the hole on the nitrocellulose star. 
Then, the second array of circles would be the detection region and the furthest out array 
of circles would be the control region.  
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Figure 20. Nitrocellulose star detection layer design 
This designed worked well for the initial tests where only two comparative samples were 
being run at once because each “limb” of the star could be cut off and placed on the back 
of the top cellulose layer. However, once the number of samples increased to all seven 
lanes, the nitrocellulose star became too fragile to work with and would rip in the center, 
making it more difficult to run a large number of tests at once. Therefore, the final design 
was changed to create a solid circle of wax-printed nitrocellulose for the second layer which 
was easier to handle and less prone to cracking and breaking. This design can be seen in 
Figure 21 and will be referred to as the final design.  
Layer one 
Layer two 
(nitrocellulose) 
Layer three Layer four Layer five 
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Figure 21. The final design for the paper-based µPAD 
This design does not include a fluid connectivity path to the bottom absorbent layer via the 
fourth layer for the final reagent wash step. This is due to the fact that the last reagent wash 
is intended to be a substrate for the enzyme on the detection pad and having it wash to the 
absorbent layer makes it difficult to accurately analyze the resultant chromogenic change. 
This is the design which will be used for the enzymatic assay tests. Before incorporation 
of the on-board reagents, however, the fluid flow through the device needed to be 
characterized.  
 
 Dye Tests 
2.4.1 Single Sample Device - Taped Assembly 
These tests were performed in order to determine the connectivity between the 
layers as well as form a baseline for the speed at which the sample would flow through the 
Layer one 
Layer three Layer four Layer five 
Layer two 
(nitrocellulose) 
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device. Since the optimization of channel widths and device timing tests had been qualified 
in previous theses under Dr. Clague, the timing of fluid flow was taken on a for-
information-only basis in order to make improvements to the device design in a go/no go 
determination [52] [53]. These tests were run with a solution made of a drop of red food 
dye in 15 mL of distilled water. All flow tests were performed using wax printed on 
cellulose paper which was subsequently melted on a hot plate for two minutes at 120°C. 
After assembly of the layers, 30 µL of the red dye solution was pipetted onto the sample 
pad and the stopwatch on an iPhone 6S was started. Three lap times were taken: 1) when 
the red dye entered the detection pad, 2) when the red dye reached the control pad, and 3) 
when the red dye reached the absorbent pad. The final time was taken as the time to 
completion of the device and was determined by lifting up the petri dish and viewing 
underneath to see when the red dye appeared on the absorbent pad. 
The first dye flow tests were performed on the one sample test strips, seen in Figure 
18 in the above section. At first, the tests were performed by adhering each layer of the 
device together onto a plastic surface using double sided tape, as seen in Figure 22 below.  
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Figure 22. Process of taping device layers together to run validation tests, in order A-H 
After wax melting was completed, the layers were cut out. Then, the absorbent pad (layer 
five) was taped down to the plastic petri dish. Following it was layers four and three, the 
fluid routing layers. Separately, the detection pad (layer two) was taped onto the underside 
of the sample pad (layer one). That assembly was then taped onto the top of layer three and 
the entire device was taped down to the petri dish again to ensure connectivity between 
layers in lieu of a housing.  
 
2.4.2 Single Sample Device - Housing Assembly 
After the initial dye routing tests, the design of the one sample flow was stable, and 
a housing was made which allowed for increased connectivity between layers and provided 
a sample port and open areas to add solution to the detection and control pads. For these 
tests, the design was printed onto cellulose with wax, melted for two minutes at 120°C, and 
E 
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cut out, as before. Now, the distal holes for the screws were cut out of each layer as well. 
The device assembly and completed device can be seen below in Figure 23.  
  
   
   
Figure 23. Process of assembling the device layers in the housing for the one sample fluid 
flow test, in order A-H 
The detection layer was taped into the cut out of layer two, seen in the first images. Layer 
one had the detection and control areas cut out in order to be able to see the detection pad 
areas below. Then, as before, the device was assembled bottom-up starting with the bottom 
of the housing with both screws inserted as guidance for alignment. Continuing by placing 
in layer five, four, three, two, and one, before adding the top of the housing with the holes 
cut out. Hex nuts were attached onto the ends of the screws and to hold the housing together 
and secure the paper layers.  
A B 
C D E
C 
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2.4.3 Rotating Assembly 
After the fluid flow within the single channel device had been completed, the final 
dimensions were translated into a rotational design with seven channels in a circular array. 
The star detection layer design, seen in Figure 20 in the previous section and in Figure 24 
below, was tested using the red dye as before.  
 
   
Figure 24. Nitrocellulose star design wax printed on cellulose and assembled, in order A-G 
Again, the pieces were cut out and assembled bottom up, with the star layer taped to the 
bottom of layer one. The device was assembled without housing and held together with the 
screws at all points within a mocked-up plastic housing to allow for rotation. After this 
A 
B C D 
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point, the device was determined to be fully functional as far as fluid flow was concerned 
and there was a low risk of wasting reagents due to an incorrectly designed, non-functional 
device. 
 
 Housing Development 
The components of the housing were held together using two methods. At first, the 
housing pieces were held together using stainless steel raised knurled-head thumb screws 
(91830A206) from McMaster-Carr®. This assembly is seen in Figure 25 below. 
 
Figure 25. Housing assembly with knurled-head screws 
 As the experiments were conducted, it became apparent that the device would 
assemble easier if the layers could be held in proper alignment while the housing pieces 
are attached. The screws would have to be inserted while the user held the device in place, 
resulting in increased risk for user error. To mitigate against this, alloy steel cup-point set 
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screw, 8-32 thread, 1-1/4" long (91375A176) were purchased from McMaster-Carr®. 
These screws could be inserted into the hex nut in the housing, as seen in Figure 26A below, 
allowing for precise assembly of the paper layers over the top of the screws. Then, the 
housing top was placed over the paper layers and hex nuts were screwed on the set screws 
to hold the housing together, as seen in Figure 26B.  
  
Figure 26. Housing with set screws, A) before device assembly and B) after device assembly 
 Enzyme Assay Development  
After the device was fully characterized in regard to layer connectivity and fluid 
flow, the next step was to design a protocol which would allow for on-board reagents that 
would create the enzymatic assay. The design of the assay was based on the enzyme-linked 
immunosorbent assay (ELISA) procedure.  
 
2.6.1 Assay Preparation Procedure 
The assay antigen and stroke biomarker, recombinant human S100B protein (LS-
G26341) was purchased from LifeSpan Biosciences, Inc®. Mouse monoclonal anti-S100B 
HRP-conjugated antibodies (ab10203) were purchased from abcam® to act as a detection 
A B 
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antibody. Mouse polyclonal anti-S100B biotin-conjugated antibodies (ab48653) were also 
purchased from abcam® to act as a capture antibody. Rat anti-Mouse IgG1 biotin-
conjugated antibody (#04-6140) was purchased from Thermo Fisher Scientific® as the 
control capture antibody against the detection antibody. Recombinant, mutant, 
nitrocellulose-binding streptavidin (Streptavidin-NC, PRO-338) was purchased from 
ProSpec® to aid in binding the capture antibodies to the nitrocellulose detection pad. TMB 
ELISA Substrate (Fast Kinetic Rate) (ab171524) was purchased from abcam® to product 
a chromogenic change in the assay when in contact with the HRP-conjugated detection 
antibody. Finally, bovine serum albumin (A9418-5G) was purchased from Millipore 
Sigma® to block the membranes and Phosphate-Buffered Saline (10010023) was 
purchased from Thermo Fisher Scientific® as a general laboratory reagent for diluting 
reagents and washing the assay. 
The antigen and the streptavidin were diluted in PBS to a concentration of 0.1 
mg/ml. The BSA was dissolved in PBS to a working concentration of 1% w/v (10 mg/ml). 
Then, all antibodies were each diluted to a concentration of 0.1 mg/ml with the PBS + 1% 
BSA.  
 
2.6.2 Assay Implementation Procedure 
In general, all of the assays followed the same basic procedure in order to maintain 
consistency between data sets. Adjustments were made for each experiment and are 
detailed in the specific experimental section.  
Printing: 
1. Print every layer but the detection layer onto cellulose paper. 
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2. Print the detection layer onto nitrocellulose paper using method described in 
previous section.  
3. Melt the wax down on a hot plate at 120°C for 2 minutes for each layer. 
4. Cut out applicable sections from each layer. 
5. Hole punch a section of glass fiber pad for each conjugate pad, as seen in Figure 27 
below (seven circles used for a full device). 
 
Figure 27. Hole-punched glass fiber for use as conjugate pads 
Creation of Conjugate Pad - Detection Antibody: 
1. Block each glass fiber pad (conjugate pad) by coating with 30 µl of 1% BSA, as 
seen in Figure 28. Let sit for 30 minutes at room temperature. 
 
Figure 28. Glass fiber pads blocked with BSA 
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2. Wash three times with 50 µl PBS by pipetting PBS onto each pad and tilting the 
dish to collect reagent at the bottom to be collected by pipette and disposed of in 
liquid waste. Dry at 37°C for 45 minutes. 
3. To each blocked glass fiber pad, add 10 µl of 0.05 mg/ml HRP-conjugated detection 
antibody in 10% sucrose and 1% BSA. Dry at 37°C for 30 minutes. 
Creation of Capture Pad - Capture Antibody: 
1. Coat exposed nitrocellulose circles on nitrocellulose pad, Figure 29, with 5 µl of 
the 0.1 mg/ml streptavidin solution. Dry at 37°C for 30 minutes.  
 
Figure 29. Nitrocellulose pad with specified holes cut out 
2. Add 10 µl of 0.1 mg/ml biotinylated anti-S100B antibody to detection pad region 
(first array of nitrocellulose circles). Add 10 µl of 0.1 mg/ml biotinylated rat anti-
mouse IgG1 antibody to control pad regions (second array of nitrocellulose circles). 
Dry at 37°C for 30 minutes. 
3. Block the nitrocellulose with 10 µl of 1% BSA solution. Let sit for 15 minutes. 
4. Wash the detection and control pads three times with 20 µl PBS. dry at 37°C for 30 
minutes.  
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Assay Demonstration: 
1. Tape conjugate pads to nitrocellulose pad, as seen in Figure 30, by aligning the hole 
punched glass fiber circles to the hole punched region on the nitrocellulose and 
adhering using double-sided tape. 
  
Figure 30. The process of attaching conjugate pads to nitrocellulose with double-sided tape, 
A) with tape backing attached and B) after tape backing is removed 
2. Tape nitrocellulose layer to the bottom of layer one, aligning the holes in layer one 
to the detection and control pads on the nitrocellulose layer, Figure 31 below. 
  
Figure 31. Front (A) and back (B) of layer one taped to the detection nitrocellulose pad 
B A 
B A 
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3. Assemble device, layer by layer, as described previously, within the housing. The 
final assembled device can be seen in Figure 32. 
 
Figure 32. Fully assembled assay device prior to sample loading 
4. Run 30 µl of S100B sample of specified concentration. Wait for all sample to be 
wicked through the device so none remains on the sample pad. 
5. Rotate, aligning the detection and control pads with the holes in the housing, as 
seen in Figure 33, and wash each pad with 30 µl PBS. Wait for all PBS to be wicked 
through to the absorbent layer. 
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Figure 33. Device after first rotation and first PBS application 
6. Rotate again, Figure 34, and wash each pad with 30 µl PBS. Wait for all PBS to be 
wicked through to the absorbent layer. 
 
Figure 34. Device after second rotation and second PBS application 
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7. Rotate again, aligning to the last circles, and add 10 µl TMB to each detection pad. 
8. Quickly, take a clear photo of the device from above. 
 
2.6.3 Image Analysis 
 Two forms of image analysis were used in order to quantify the intensities of the 
color appearing on each detection pad. First, the MATLAB code created by Van Huynh 
(2016) was utilized, following the user instructions prompted by the code in order to return 
average intensity values with arbitrary units [58]. ImageJ was used once it became clear 
that the MATLAB code did not provide the level of specificity required for the assay. The 
ImageJ software was used in conjunction with a downloaded plugin called “RBG Measure” 
[59]. This plugin was used to calculate the average red, blue, and green values within each 
detection region of an image in order to better quantify the control region as background. 
For this form of analysis, the background was removed with the ImageJ rolling ball setting 
at 50 pixels, the image was inverted, and the red, green, and blue (RGB) values were 
measured for each region of interest, i.e. the detection pads. Then, the R, G, and B values 
were averaged for each region of interest to obtain an average color intensity for each 
sample and the control. Finally, the average color intensity of the sample was divided by 
that of the control in order to obtain a signal-to-noise ratio. 
 
2.6.4 Antibody Analysis  
The first assay experiment was completed using the nitrocellulose star design, seen 
in Figure 20 above. The purpose of this experiment was to determine if the purchase 
antibodies and antigen interacted properly with each other and could develop a blue color 
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signal. The device was run with 10 µl of 0.1 mg/ml HRP conjugated antibody in PBS + 
10% sucrose and 0.1% BSA, 10 µl of 0.1 mg/ml biotinylated anti-S100B antibody, and 30 
µl of 0.1 mg/ml S100B antigen. The assay was otherwise run as described in the Assay 
Implementation Procedure section.  
 
2.6.5 Streptavidin Characterization 
A side experiment was conducted to investigate the use of streptavidin + biotin on 
the detection pad. As mentioned, the streptavidin purchased for this thesis was a mutant, 
nitrocellulose-binding streptavidin protein. This protein was purchased with the thought 
that it would bind better to the detection pad and therefore binding to more of the 
biotinylated capture antibody and preventing the reagents washing off with the sample fluid 
front or PBS washes. The efficacy of this protein was investigated by comparing it to native 
streptavidin (ab136200) from abcam® and to a control detection pad without any 
streptavidin. On three detection pads, 5 µl of 0.1 mg/ml mutant streptavidin was deposited. 
On another three detection pads, 5 µl of 0.1 mg/ml native streptavidin was deposited. The 
seventh detection pad was treated with 5 µl of PBS as a control. Then, as in the protocol, 
the biotinylated anti-S100B antibody was deposited and dried, followed by a BSA blocking 
step. Then, after device assembly, 30µl of 1 ng/ml S100B protein was added to each sample 
pad. The rest of the experiment was run as in the protocol.  
 
2.6.6 Optimization of Detection Antibody 
 The second major experiment conducted was to determine the effect that the 
concentration of HRP-conjugated anti-S100B antibody has on the sensitivity of the assay 
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on this particular device. To optimize this parameter, the concentration of detection 
antibody was varied between 0.01 mg/ml to 0.1 mg/ml with a blank included. The antibody 
was serially diluted in PBS + 1% BSA + 10% in order to return the following 
concentrations: 0.1 mg/ml, 0.08 mg/ml, 0.06 mg/ml, 0.04 mg/ml, 0.02 mg/ml, 0.01 mg/ml, 
and a 0 mg/ml diluent blank. The assay was run in triplicate using 30 µl of 0.1 µg/ml S100B 
sample. 
 
2.6.7 Determination of Limit of Detection 
Then, the assay was tested with a panel of protein concentrations in order to 
determine the limit of detection (LOD), defined as the lowest analyte concentration which 
can be reliably differentiated from a blank [60]. The aim was to derive a standard curve, 
similar to that of an ELISA, which follows a sigmoidal shape when plotting analyte 
concentration versus the signal-to-noise ratio. To achieve this, a serial dilution of S100B 
was performed to cover a range of 0.1 mg/ml to 1E-4 pg/ml in order to get a complete range 
of responses.  
 
2.6.8 Analysis of Troponin-Based Assay 
The previous thesis completed by Holler (2016) was not able to display full device 
functionality with on-board reagents, specifically, in regard to the detection antibody 
loaded onto and resolubilized from the conjugate pad. In that work, the conjugate pad was 
made out of cellulose paper, as compared to the glass fiber used for the device in this thesis. 
In order to conduct an initial investigation into whether this pad material had an effect on 
the functionality of the device and the resolubilization of the detection antibody, the 
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reagents used by Holler (2016) were incorporated into the device created for this thesis 
using the protocol established above. Since the previous work of Holler (2016) used 
troponin as the analyte, this investigation was also meant to establish ground work as to 
whether the device and protocol could be adapted to a protein other than S100B. 
First, the anti-cardiac troponin I capture antibody (ab47003) was biotinylated using 
the Biotinylation Kit/Biotin Conjugation Kit (Fast, Type B) (ab201796) following the 
associated kit protocol. Following the streptavidin application, as in the protocol, 10 µl of 
capture antibody was loaded onto the device, four detection pads at 1.6 mg/ml and three 
detection pads at 0.1 mg/ml in order to get a range for device detection ability, which had 
not been established. The HRP anti-cardiac troponin detection antibody (ab10239) was 
deposited onto the glass fiber conjugate pad, 10 µl at 0.05 mg/ml. The assay was assembled 
and run with 30 µl of 1 ng/ml troponin protein (ab9936).  
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3. RESULTS 
This portion of the report will summarize the results from the experiments performed 
in order to fully validate the development of the paper-based µPAD with ELISA-like 
technology integrated within the device.  
 
 Analysis of Previous Work 
After running red dye through the sample port of Alicia Holler’s previous design 
assembled within her housing, the device was taken apart to visualize the fluid flow 
pathway. This can be seen in Figure 35 below. 
 
Figure 35. Fluid flow analysis of Holler's design with red dye 
 Dye Tests 
3.2.1 Single Sample Device - Taped Assembly 
 The first characterization tests of the new design were completed on single-channel 
devices, with which the design could be quickly and efficiently changed to adapt to the 
results before being implemented into the rotational design. Several trials of this design 
were run where each layer was taped together; however, five trials out of the six trials did 
not see proper fluid routing, and, while care was taken to assemble the device as accurately 
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as possible, the tape method was not substantial enough to provide fluid flow data. Most 
often, it was observed that the fluid front stopped after the detection pad before reaching 
the control pad. The reasoning behind this will be analyzed further in the Discussion.  
The one complete trial can be seen in the figures below, in which the red dye has 
been placed on the sample pad, the second circle from the top on the device, and was able 
to flow through the entirety of the device, appearing on both the detection pad and the 
sample pad,  the following circles, third and fourth from the top.  
  
Figure 36. Progression of red dye through single sample device, A) at detection pad and B) 
at control pad region 
The time was taken as described in the Methods. The elapsed time for the trial is 
summarized in Table II below. 
Table II. Development Time for Single Sample Fluid Flow 
 
Time to Detection Pad 
(seconds) 
Time to Control Pad 
(seconds) 
Time to Absorbent Pad 
(seconds) 
Trial 1 14.80 ± 0.2 45.51 ± 0.2 138.54 ± 0.2 (2:18.54 minutes) 
 
B A 
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3.2.2 Single Sample Device - Housing Assembly 
 Once the design of the single sample device had been finalized, a housing was 
created and used to test further iterations to better approximate the fluid flow that would 
be expected in the final rotating device. The progression of fluid flow can be seen in Figure 
37 below: 
   
Figure 37. Flow of red dye through single sample device with housing, A-C as time elapses 
When taken apart, one can see that the red dye was able to flow through the device 
via the channels, successfully reaching the absorbent pad within the housing, as seen in 
Figure 38.  
  
Figure 38. Results of fluid flow testing of single sample device; A) top of layer one and B) 
bottom of layer one showing the detection pad 
A B C 
B A 
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In all trials, the time was taken as described in the Methods. The elapsed time for 
each trial is summarized in Table III below. 
Table III. Development Times for Single Sample Device with Housing 
 
Time to Detection Pad 
(seconds) 
Time to Control Pad 
(seconds) 
Time to Absorbent Pad 
(seconds) 
Trial 1 17.75 ± 0.2 77.53 ± 0.2 210.13 ± 0.2 (3:30.13 minutes) 
Trial 2 12.30 ± 0.2 46.71 ± 0.2 139.25 ± 0.2 (2:19.25 minutes) 
Trial 3 14.65 ± 0.2 43.96 ± 0.2 133.36 ± 0.2 (2:13.36 minutes) 
 
These results were averaged and the standard deviation of each was determined, as seen in 
Table IV below. 
Table IV. Average Development Times for Single Sample Device with Housing 
Average 
Time to 
Detection 
Pad (s) 
Standard 
Deviation 
of Time to 
Detection 
Pad (s) 
Average 
Time to 
Control 
Pad (s) 
Standard 
Deviation 
of Time to 
Control 
Pad (s) 
Average 
Time to 
Absorbent 
Pad (s) 
Standard 
Deviation of 
Time to 
Absorbent 
Pad (s) 
14.9 ± 0.2 2.73 56.07 ± 0.2 18.64 160.91 ± 0.2 42.72 
 
3.2.3 Rotating Assembly 
 The finalized dimensions from the single sample devices were then translated into 
a rotational design, as described in the Methods section, and included additional channels 
which could be used as wash steps. This design was also tested for fluid flow characteristics 
with red dye. The assembled device can be seen in Figure 39 below, both within the housing 
and disassembled to visualize the flow path. 
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Figure 39. Results of rotational design for characterization of fluid flow, A) assembled and 
B) disassembled 
As before, the time for the dye to flow through the device was taken for each trial and is 
displayed in Table V below.  
Table V. Development Times for Rotational Device 
 Time to Detection Pad 
(seconds) 
Time to Control Pad 
(seconds) 
Time to Absorbent Pad 
(seconds) 
Trial 1 43.05 ± 0.2 84.46 ± 0.2 123.56 ± 0.2 (2:03.59 minutes) 
Trial 2 29.13 ± 0.2 60.66 ± 0.2 121.94 ± 0.2 (2:01.94 minutes) 
Trial 3 29.86 ± 0.2 78.84 ± 0.2  
136.14 ± 0.2 
(2:16.14 minutes) 
Trial 4 19.38 ± 0.2 64.71 ± 0.2 133.01 ± 0.2 (2:13.01 minutes) 
 
The average and standard deviation of each point was also calculated and can be found in 
Table VI below. 
B A 
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Table VI. Average Development Times for Rotational Device 
Average 
Time to 
Detection 
Pad (s) 
Standard 
Deviation 
of Time to 
Detection 
Pad (s) 
Average 
Time to 
Control 
Pad (s) 
Standard 
Deviation 
of Time to 
Control 
Pad (s) 
Average 
Time to 
Absorbent 
Pad (s) 
Standard 
Deviation of 
Time to 
Absorbent 
Pad (s) 
30.36 ± 0.2 9.72 72.17 ± 0.2 11.31 128.66 ± 0.2 6.98 
 
 Enzyme Assay Development  
3.3.1 Antibody Reactivity Analysis  
 The first assay performed on the device was to determine the reactivity between the 
antigen and the antibodies. A photograph of the device was taken after TMB had been 
added, as seen in Figure 40. 
 
Figure 40. Colorimetric result of antibody analysis test 
The image in the above figure was opened in ImageJ and the intensity of each sample and 
control was taken in order to determine a signal-to-noise ratio, calculated by dividing the 
sample intensity by the control intensity. The two tests were run utilizing the same 
 71 
protocols, so the percent difference between the two ratios was taken in order to quantify 
the repeatability of the results. The average and standard deviation are below in Table VII. 
Table VII. Color Intensity of Initial Reactivity Tests 
 Intensity Signal-to-Noise Ratio 
Trial 1 50.385 3.5613 
Trial 2 48.054 3.3965 
Control 
(background) 14.148 1.0000 
Percent Difference 4.7359 
Average 3.4789 
Standard Deviation 0.1165 
 
3.3.2 Streptavidin Characterization 
A device was run with two types of streptavidin (mutant and native) in triplicate 
placed on the detection pad prior to loading with a biotinylated anti-S100B antibody and 
tested against with 1 ng/ml S100B. The device can be seen in the figure below. 
 
Figure 41. Device used to characterize mutant vs native streptavidin 
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ImageJ was used to analyze the intensity of each detection pad and the average for each 
trial was taken, along with the standard deviation, as displayed in Table VIII below. 
Table VIII. ImageJ Analysis of Streptavidin Assay 
 Average 
Intensity 
Average  
Signal-to-Noise 
Standard 
Deviation 95% CI 
Mutant 
Streptavidin 85.51 2.41 0.139 (2.037, 2.776) 
Native 
Streptavidin 67.22 1.89 0.295 (1.522, 2.261) 
Control 74.69 2.10 -- (1.462, 2.742) 
Background 35.54 1.00 --  
 
After conducting an ANOVA on the dataset, it was determined that the p-value was 
0.121, which, since it is larger than 0.05, means that the data is not statistically different. 
 
3.3.3 Optimization of Detection Antibody 
 This experiment was used to determine the appropriate concentration of detection 
antibody to load onto the conjugate pad. Figure 42 below shows the final result of one of 
the trials of the experiment. 
 
Figure 42. Colorimetric result for trial one of optimization of detection antibody tests 
 73 
The times were also taken for each device in order to compare to the fluid routing trials 
and can be seen in the table below. 
Table IX. Time for Development of Detection Antibody Optimization Trials 
 Time to Detection Pad 
(seconds) 
Time to Control Pad 
(seconds) 
Time to Absorbent Pad 
(seconds) 
Trial 1 37.45 ± 0.2 216.32 ± 0.2 366.87 ± 0.2 (6:08.87 minutes) 
Trial 2 25.18 ± 0.2 154.51 ± 0.2 282.27 ± 0.2 (4:42.27 minutes) 
Trial 3 41.95 ± 0.2 175.25 ± 0.2 300.67 ± 0.2 (5:00.67 minutes) 
 
The average and standard deviation of each point was also calculated and can be found in 
Table X below. 
Table X. Average Development Times for Detection Antibody Optimization Trials 
Average 
Time to 
Detection 
Pad (s) 
Standard 
Deviation 
of Time to 
Detection 
Pad (s) 
Average 
Time to 
Control 
Pad (s) 
Standard 
Deviation 
of Time to 
Control 
Pad (s) 
Average 
Time to 
Absorbent 
Pad (s) 
Standard 
Deviation of 
Time to 
Absorbent 
Pad (s) 
34.86 ± 0.2 8.67 182.02 ± 0.2 31.45 316.60 ± 0.2 44.49 
 
The image was also analyzed using ImageJ, as specified in the Methods. The results of the 
signal-to-noise ratios of the samples compared to the blank controls on each trial are plotted 
below. 
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Figure 43. All trials of signal quality in dependence of detection antibody concentration 
The signal to noise ratios for each trial were averaged for each concentration and the results 
are displayed in Figure 44 below, including error bars ± 1 SD. 
 
Figure 44. Signal quality in dependence of detection antibody concentration 
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3.3.4 Determination of Limit of Detection 
The results for the response of the device to different analyte concentrations is 
shown below.  
  
Figure 45. Assay response to different analyte concentrations, A) high set of concentrations 
and B) low set of concentrations 
Some of these devices were also run using the control antibody on the control pad 
(furthest out ring of circles), which are used to determine if the test ran properly with 
enough sample. This can be seen in Figure 46 below, where all of the detection and control 
pads are blue, indicating a positive test that ran correctly. 
 
Figure 46. Device showing control pad functionality 
B A 
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The times were also taken for each device in order to compare to the fluid routing 
trials and can be seen in the table below, ± reaction time. 
Table XI. Development Times for Dose Response Device Trials 
 Time to Detection Pad 
(seconds) 
Time to Control Pad 
(seconds) 
Time to Absorbent Pad 
(seconds) 
Trial 1 32.86 ± 0.2 188.40 ± 0.2 452.67 ± 0.2 (7:32.67 minutes) 
Trial 2 30.87 ± 0.2 215.12 ± 0.2 328.38 ± 0.2 (5:28.38 minutes) 
Trial 3 27.63 ± 0.2 312.26 ± 0.2 504.15 ± 0.2 (8:24.15 minutes) 
 
The average and standard deviation of each point was also calculated and can be found in 
Table XII below. 
Table XII. Average Development Times for Dose Response Trials 
Average 
Time to 
Detection 
Pad (s) 
Standard 
Deviation 
of Time to 
Detection 
Pad (s) 
Average 
Time to 
Control Pad 
(s) 
Standard 
Deviation 
of Time to 
Control 
Pad (s) 
Average 
Time to 
Absorbent 
Pad (s) 
Standard 
Deviation of 
Time to 
Absorbent 
Pad (s) 
30.45 ± 0.2 2.64 238.59 ± 0.2 65.18 428.40 ± 0.2 90.36 
 
The images were also analyzed using ImageJ. The signal to noise ratios for each 
trial were averaged for each concentration and the results are displayed below. The data 
was fitted to a Four parameter logistic (4PL) curve which is commonly used to display 
ELISA results because it follows a sigmoidal “S” shape which appropriately approximates 
the colorimetric change across concentration ranges. MATLAB was used to fit the curve 
to the expression [61]: 
𝑦 = 𝑑 +	 𝑎 − 𝑑[1 + O𝑥𝑐QR] 
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Wherein:  
a is the minimum value that can be obtained; expected at 0 dose concentration; 
d is the maximum value that can be obtained; 
c is the point of inflection; and 
b is Hill’s slope of the curve at the inflection point [62]. 
The MATLAB code returned the following results which can be seen plotted with the data 
compiled from the dose response trials, ± standard deviation, corrected for outliers. The 
raw data can be found in the Appendix. 
 
Figure 47. Dose response for different analyte concentrations fit to a 4PL regression curve 
The equation for the 4PL fit was determined, shown below, with an R2 value of 0.9365 
indicating a good fit to the data.  
𝑦 = 2.527 + 1.141 − 2.5271 + O 𝑥2.367QY...(Z 
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In order to determine the LOD, the average intensity value of the blanks used was 
added to three times the standard deviation of the blank [63]: 𝐿𝑂𝐷 = 𝐴Y + 3 ∗ 𝜎 
This intensity LOD value was then plugged into the returned 4PL equation for the intensity 
versus concentration of S100B graph, found in the Appendix, which returned a value for 
the LOD in ng/ml. It was determined that the LOD for the device is 147.9 pg/ml. Since 
human S100B has a molecular weight of 12.5 kDa, the LOD was calculated to be 11.83 
pM (1.1832x10-11 M) [63].  
 
3.3.5 Analysis of Troponin-Based Assay 
The results for the paper-based microfluidic device enabled to detect troponin can 
be seen in Figure 48 below.  
 
Figure 48. Results of troponin-enabled detection assay device 
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Six of the trials were run with protein while the seventh trial was run with PBS as a 
background control. The results from the ImageJ analysis can be seen in the table below. 
Table XIII. ImageJ Analysis Results for the Troponin-Enabled Assay 
 Average 
Intensity 
Average 
Signal-to-Noise 
Standard 
Deviation 
1.6 mg/ml Capture Ab 78.10 1.49 0.2932 
0.1 mg/ml Capture Ab 72.90 1.39 0.0969 
Control (background) 52.41 1.00 -- 
 
An ANOVA was also conducted on this data set and returned a p-value of 0.338, which 
means that, at a significance level of 0.05, the data was not statistically significantly 
different.  
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4. DISCUSSION 
 This section will be used to analyze the data presented in the previous section in 
order to draw conclusions about the fabrication and functionality of the assay and its 
housing. 
 
 Analysis of Previous Work 
The previous design (Holler, 2016) printed on cellulose was functionally able to 
route red dye through each layer, which could be seen in the Results. This verifies the 
ability to route fluid through the device successfully. This result provides a foundation for 
the assay design which can be built upon in order to improve the functionality of the 
ELISA-like assay; however, Holler was unable to integrate the ELISA-like assay onto the 
device, likely due to her protocol for reagent storage on and resolubilization from the 
conjugate pads. The aim of the rest of the discussion will be to determine if the ELISA-
like assay could be successfully implemented on the updated device design.  
 
 Dye Tests 
 Several trials of each dye test were performed in order to gather accurate 
information about the functionality of the fluid flow pathway of the assay. While 3D 
µPADs have been created using wax-printing techniques and the base format of routing up 
and down through layers had been demonstrated by Holler (2016), the design change was 
substantial enough to warrant testing before moving forward with reagent incorporation. 
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4.2.1 Single Sample Device - Taped Assembly 
 The first trials of fluid flow were completed using the design wax-printed on 
cellulose and taped together onto a plastic petri dish to aid in layer-to-layer connectivity. 
The initial trials were not successful, as the fluid flow was stopped after the detection pad, 
but before the control pad, in the area marked in Figure 49A below. This can also be seen 
in Figure 49B, where the red dye stopped in the fluid routing layer and did not reach the 
fourth layer or the absorbent pad.   
 
 
Figure 49. Single sample fluid flow design with A) flow barrier area marked in red on 
AutoCAD design and B) results from an incomplete trial 
Across all of the trials, there was inconsistency with lining up the channels between layers 
and providing ample pressure to ensure that the layers were in contact with each other in 
the proper places. If the layers were not placed together precisely, the fluid would become 
trapped at a barrier, where it would be unable to transition up or down to continue to flow 
laterally. Due to the region of impedance, it was determined that the wax bridge was too 
thick and was causing a blockage in the flow pathway if the layers became misaligned, 
B A 
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which would have been further perpetuated without sufficient pressure externally to 
provide layer connectivity. Due to this, the thicknesses of the wax bridges were decreased, 
and more care was taken to precisely align the layers with tape. 
As can be seen in the Results section, the design of the single sample device was 
eventually able to successfully route the red dye through from the sample pad, up to the 
detection pad and subsequently the control pad, flowing down to the absorbent pad. Since 
the red dye can be seen in each exposed pad, as well as within the hydrophilic cellulose 
channels when the device was taken apart, it was deemed a successful trial of the design. 
There were no issues seen with fluid “overflowing” from the paper channels over onto the 
wax areas between layers. A total development time of 2:18.54 minutes was initial 
validation that the device would be able to quickly bring the patient sample through to the 
correct reagents in order to yield a positive or negative result.  
 
4.2.2 Single Sample Device - Housing Assembly 
  With the challenges faced when prototyping the single channel design with tape 
between layers, it was determined that a housing would need to be created to properly 
demonstrate the functionality of the intended final design. The housing would help both 
with providing ample pressure throughout the device, as well as aiding in the alignment of 
each layer. The screws would be used to hold the top and bottom housing components to 
each other, and when the screw holes in each layer were cut out and inserted over the 
screws, it became increasingly easier to assemble to device correctly, since the screws 
prevented shifting of layers and were used as guides for how the layers were intended to 
be placed.  
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Once the red dye fluid flow trails were conducted in this housing, more meaningful 
data was able to be obtained concerning development time and overall success in fluid 
routing. As can be seen in the Results, the dye front flowed successfully through to device 
across all three trials. The mean development time was 2:40.91 minutes with a standard 
deviation of ± 42.72 seconds. The first trial resulted in the longest development time, 
whereas the subsequent two trials had very similar development times, at approximately 2 
minutes. The largest standard deviation occurred in the time between the control pad to the 
absorbent pad, where the other two time points had relatively small standard deviations for 
the three trials. This could be because the first trial did not have proper alignment between 
the routing layers (layers three and four) which rely on the overlap of two thin rectangular 
regions. Therefore, a shift in the alignment would most noticeably impact the flow down 
to the absorbent pad due to the smaller area of overlap when compared to elsewhere in the 
device. However, since the speed of the device was sufficiently fast in comparison to 
existing diagnostic techniques, and it was not intended to be optimized further, the single 
sample design was considered finalized and the dimensions were transformed into a seven-
sample circular device in a rotating assembly.  
 
4.2.3 Rotating Assembly 
Upon finalizing the design for the single sample design, the rotating design was 
printed and assembled and tested for fluid flow as well, to ensure that the translation 
between one sample to seven samples maintained the functionality of the device. These 
trials were run using a mocked-up housing made from plastic sheeting that was faster and 
cheaper to make than the final acrylic housing but would still give accurate data. All four 
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trials of the rotating design printed on cellulose paper were successful, with fluid routing 
efficiently between each layer down to the absorbent pad. The average development time 
was determined to be 2:08.66 minutes, with a standard deviation of ± 6.98. This time data 
deviated less between each trial than the single sample flow design, which would indicate 
that the extra points of pressure from the seven screws along the outside of the device and 
the single screw in the center created better pressure and alignment between layers. When 
taken apart, the red dye could be seen in all intended flow paths, including the first sample 
channel and the three subsequent wash step channels, also run with red dye. These trials 
were promising for the success of the device when considering the ability of the sample to 
reach each area for the specific reaction step and flow entirely through the device to fully 
develop a signal that could be read by the user when the proper reagents were incorporated 
into the device.  
 
 Enzyme Assay Development  
 After successfully designing the device to route fluid through the intended 
pathways at a rapid pace, the next step was to incorporate the ELISA-like reagents onto the 
platform so that a diagnostic test could be run from a sample. These experiments used the 
full set up of the device, including a nitrocellulose detection pad as opposed to the cellulose 
which had been used in the fluid flow experiments, a separate glass fiber conjugate pad for 
the HRP-conjugated antibody, and the inclusion of the reagents for reactivity. 
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4.3.1 Antibody Analysis  
 In the first trial of the ELISA-like assay incorporation of the device, two identical 
tests were run to determine if the antibodies and antigen purchased were reactive and if the 
test would be able to return a discernable color change with the addition of the HRP 
substrate, TMB. This test was also used to determine the precision of the ImageJ analysis 
method. As seen in the Results, the incorporation of on-board reagents was successful, and 
the test was able to run to completion, as indicated by the blue color on the detection pads. 
The sample – PBS spiked with 0.1 mg/ml S100B – was able to resolubilize the detection 
antibody on the conjugate pad, something which was not realized in the previous work 
(Holler, 2016), and the fluid front could carry the detection antibody and S100B complex 
to the detection pad to bind to the capture antibody and return a visual result when reacted 
with TMB. When comparing the values returned for intensity from the ImageJ intensity 
analysis, the percent difference between the two was low (below 5%) and indicated, along 
with the standard deviation (0.1165) that the software was able to return results in an 
accurate and repeatable fashion.  
These two trials were considered successes because now the protocol used to set up 
the device was determined to be appropriate in yielding the desired result, and the 
parameters could be changed in subsequent experiments in order to optimize the device. 
 
4.3.2 Streptavidin Characterization 
The necessity of the streptavidin + biotin binding reaction for the functionality of 
the device was analyzed in an experiment which compared final color intensity and signal-
to-noise of the assay run with S100B against a biotinylated antibody bound to mutant 
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streptavidin, native streptavidin, and a control without streptavidin. After an ANOVA was 
conducted on the data, the p-value was determined to be 0.121, which is larger than 0.05, 
meaning that the average values for signal-to-noise were not statistically different from one 
another. Therefore, with the three trials, it can be concluded that the type of streptavidin, 
or lack thereof, did not have a significant effect on the signal. This is interesting because, 
in theory, the nitrocellulose only non-specifically binds to the antibodies, leaving them 
susceptible to being washed off of the detection pad. Therefore, the streptavidin + biotin 
pair would be used to encourage binding to the nitrocellulose and minimize sample loss. 
Further testing would need to be done with a larger data set in order to determine if the 
mutant vs native streptavidin has a functional difference with binding between 
nitrocellulose and the biotinylated antibody. 
 
4.3.3 Optimization of Detection Antibody 
 The concentrations and quantities of reagents used in the first experiment were 
drawn from research into literature which used a similar principle of incorporation of an 
ELISA-like assay onto a paper-based device. These values were used to determine a 
baseline for the feasibility of obtaining a visible signal, and once that was achieved, 
changes were made to the protocol that would allow the device to run off of minimal 
amounts of reagents in order to reduce costs and eliminate background noise caused 
specifically by excessive antibodies.  
 In this experiment, the concentration of the HRP-conjugated detection antibody 
was varied in order to determine the critical concentration where there is sufficient antibody 
to produce an accurate signal by binding with a majority of the antigen but there is not too 
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much so that there is surplus of unbound antibody on the detection pad which is still 
returning a positive result by catalyzing the TMB. When the detection antibody is at too 
low of a concentration, the antigen will not be bound and only a portion of it would return 
a signal, meaning that the device would return a signal that indicates that the antigen 
concentration in the sample is lower than it is in reality. When the detection HRP-
conjugated antibody is at too high of a concentration, any unbound antibody has a higher 
chance of nonspecifically binding onto the detection pad after the wash steps and producing 
a color change, indicating a positive result when, in reality, no antigen is bound, leading to 
a result which indicates that the antigen concentration in the sample is higher than it is in 
reality. There is, therefore, a concentration of HRP-conjugated detection antibody which 
will allow for the accurate and specific binding of the antigen and only result in a 
colorimetric result when the full immunocomplex is created on the detection pad. 
 The devices which were run with the control pad suffered from timing issues with 
the color development due to the fact that the user needed to manually pipette 14 regions 
with TMB as opposed to only 7 in the tests without a control pad. Since the control pad 
would not be analyzed for color intensity and is functioning as a “yes/no” result due to blue 
color/no color change, the detection pads were pipetted first and a photo was taken before 
the TMB was pipetted onto the control pad to test for device functionality. 
 The time for development of each trial was taken in order to quantify the time for 
detection. The average time for the sample to completely flow to the absorbent pad was 
calculated to be 5:16.60 minutes with a standard deviation of ± 44.49 seconds between 
each trial. This speed was slower than the development times seen in the previous fluid 
flow trials likely due to the inclusion of the glass fiber conjugate pad and the nitrocellulose 
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layer as compared to the fluid flow tests which were run entirely on cellulose paper. The 
detection antibody on the conjugate pad was also dried down in a PBS solution with 10% 
sucrose to aid in protein stability, and the sucrose would have impeded the flow of the 
sample through the device because the sample must resolubilize the sucrose before 
continuing on to the detection region [35]. While this slowed down the development times, 
it would theoretically be a positive because the sample and the analyte within would have 
a longer incubation time with the detection antibody on the conjugate pad than it would 
without the sucrose. 
All of the trials for this experiment were graphed and displayed in the Results. As 
seen in this graph, each trial follows the same trend but at different magnitudes of signal-
to-noise. It can be concluded that the intensity of the sample area, as determined by ImageJ, 
is highly dependent on the photograph taken, specifically the lighting. However, since the 
plots follow the same trend, it can also be inferred that the data was consistent between 
trials, even though the actual numbers were not the same.  
As can be seen in the Results, the graph of detection antibody versus average signal-
to-noise ratio increased when moving from a low concentration of 0.01 mg/ml up to 0.04 
mg/ml. This is in accordance with the expectations – the more HRP-conjugated antibody 
on the conjugate pad, the higher the intensity of the signal and therefore the higher the 
signal relative to the noise. Then, between 0.04 mg/ml and 0.08 mg/ml, there is a plateau 
in the signal-to-noise ratio, which indicates that the critical concentration had been reached 
and the signal-to-noise ratio was not improving with the addition of more detection 
antibodies. Then, at a concentration of 0.1 mg/ml, the signal-to-noise ratio increased 
dramatically, which is indicative of unbound HRP-conjugated detection antibody 
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nonspecifically binding to the nitrocellulose and not getting fully washed away by PBS and 
therefore still resulting in what is read as a positive signal, when in actuality, no antigen 
has been bound. When looking at the raw data, it was determined that a high signal-to-
noise ratio for one trial of 0.08 mg/ml was elevating the average value up to the 0.04 mg/ml 
and 0.06 mg/ml concentrations, when it was actually likely a bit lower, indicating a 
decrease in the signal relative to the background noise before the increase up to 0.1 mg/ml. 
Therefore, it was determined that the optimal concentration of the HRP-conjugated 
detection antibody was 0.05 mg/ml, half as much as the highest signal response and still 
within the plateau region of the graph as the average between 0.04 and 0.06 mg/ml.  
 The graph also shows error bars ± 1 standard deviation. These bars are considerably 
large due to the fact that the intensity values are calculated from a picture taken of each 
device at the end of the trial under variable lighting, as briefly discussed above. This means 
that while there is consistency in intensity within each trial because the photo is analyzed 
in reference to a control which is on the device, there is inherent inconsistency between 
trials for the intensity values. This is why the trend seen in the signal-to-noise data for each 
trial was considered as opposed to purely the values for intensity. In essence, the average, 
the +1 SD, and -1 SD values respectively correspond to each trial conducted and the 
variability was expected but does not affect the results.   
 
4.3.4 Determination of Limit of Detection 
The final round of experiments conducted were to determine the limit of detection 
(LOD) of the device. This is important because the LOD is the lowest concentration of 
protein which can be accurately and repeatedly differentiated from a blank control. The 
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LOD is a measure of the functionality of the clinical ability of the device. The LOD must 
be lower than the concentration of protein expected to be expressed in the patient sample 
when the disease or pathology is present so that said disease can be detected and diagnosed.  
These experiments varied the concentration of antigen (S100B) applied onto the 
sample pad in order to obtain a standard curve of antigen concentration versus signal-to-
noise or intensity, theoretically resulting in a sigmoidal shape. The reason for this shape is 
that the concentrations of antigen become too low to detect at a certain concentration and 
too high to differentiate at another certain concentration, causing the concentrations at the 
extreme low and high concentrations to return the same intensity values and therefore the 
same signal-to-noise values. Effectively, there exists a linear range of antigen 
concentrations in which the assay can sensitivity and specifically differentiate the 
concentration.  
In these experiments, the concentration of capture antibody was kept at 0.1 mg/ml, 
the concentration of detection antibody was maintained at 0.05 mg/ml, per the previous 
optimization experiments, and the concentration of the S100B was varied from 0.0001 
ng/ml to 100,000 ng/ml via ten 10-fold dilutions. This was intended to be sufficient to cover 
the entire range of the detection spectrum so that the linear area could be found between 
the extreme high and low concentrations. It can be seen in Figure 45 that the tests ran 
successfully and resulted in the blue color. The same reaction occurred as described in the 
previous section: PBS + S100B resolubilized the conjugate antibody and bound, then 
traveled to the detection pad to bind to the capture antibody for eventual catalysis of TMB 
by HRP. 
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The times for three of the trials were also taken, resulting in an average time to the 
absorbent pad of 7:08.40 minutes with a standard deviation of ± 90.36 seconds. Again, 
these times had large standard deviations between trials, likely due to misalignments 
between the layers. The fastest time to the absorbent pad recorded was 5:28.38 minutes, 
which, when including the rotation, wash steps, and TMB addition, amounts to 
approximately 15 minutes to run the entire device and return a colorimetric response. This 
is magnitudes faster than the current gold standard; CT scans can take up to 60 minutes 
and contrast solution must be injected to see an ischemic stroke [64]. 
Each trial was photographed immediately after introduction of the TMB and 
analyzed by ImageJ for RGB signal intensity. These results can be seen in Figure 47, where 
the results were plotted against the calculated signal-to-noise ratio determined by a control 
on each device run. A sigmoidal 4PL curve was fit to the data using MATLAB code [61]. 
There exists a clear trend following the expected sigmoidal shape which spans the entire 
concentration range, with a linear region in the center from 0.01 ng/ml to 1000 ng/ml, 
which would correlate to an approximate detection range. It is important to consider that 
the device runs similar to an ELISA and a standard curve of known concentrations would 
need to be run with the sample so that the standard curve could be created, and the 
concentration of the sample extrapolated from that based on the relative intensity. 
Further, the 4PL regression curve was fit to signal intensity vs S100B concentration 
to determine the LOD. As stated in the results, the LOD was determined to be 147.9 pg/ml 
(11.83 pM). This is within the range of sensitivity for commercial ELISAs for human 
S100B, which are cited between 19.5 pg/ml (1.56 pM) to 0.31 ng/ml (24.8 pM) [65] [66]. 
Clinically, S100B has been cited to be a biomarker for ischemic stroke at levels above 
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1,030 pg/ml, 350 pg/ml, and 115.03 pg/ml [67] [68] [69]. Therefore, the ELISA-like device 
developed for this thesis hold clinical significance in detecting S100B in order to diagnose 
ischemic stroke.  
 
4.3.5 Analysis of Troponin-Based Assay  
The final test which was conducted was an analysis of the device using a different 
set of proteins and antibodies used for a previous thesis (Holler, 2016). While the test was 
only to see if the proteins used in the past work were functional for use on a paper-based 
device and to determine if the designed device would be able to detect other proteins if the 
on-board reagents are changed, the signal-to-noise ratios were compared between the two 
concentrations of capture antibody. The p-value returned for the ANOVA was greater than 
the 0.05 significance level and therefore was not statistically significant. Therefore, the 
concentration of capture antibody on the detection pad was not significant on the signal-
to-noise result.  
This test, however, did show that the device was able to return a readable result for 
the detection of troponin using antigens and antibodies from the previous thesis (Holler, 
2016). These antibodies had been stored in -20°C conditions for the past three years, and 
while the detection pad exhibited a color change, this could have been due to a false 
positive of non-specific binding of the detection antibody to the nitrocellulose. Further 
experimentation would need to be conducted with freshly purchased antigen-antibody 
pairings for improved validation. Beyond demonstrating the adaptability of the device to 
be used with different analytes with the specific on-board antibodies, this experiment was 
able to conclude that the likely reason that the previous work was unable to realize a fully 
functional device with on-board detection antibody was that the cellulose conjugate pad 
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used by Holler (2016) is not suitable for antibody storage and eventual resolubilization 
with sample introduction. A more effective alternative would be the glass fiber conjugate 
pad used in this device which was able to hold the HRP-conjugated detection antibody, 
resolubilize it to allow it to react with the analyte and carry it onward to the detection pad 
where the capture antibody is bound for eventual detection with TMB.   
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5. CONCLUSION 
 This thesis demonstrates the ability for a 3D paper-based microfluidic device to 
incorporate an ELISA-like test on its platform in order to detect clinically significant 
concentrations of S100B in order to diagnose ischemic stroke. A prototype of a low-cost, 
highly sensitive, and easy-to-use portable device was achieved with the incorporation of 
on-board reagents onto the paper platform. This device was created using wax printing 
hydrophilic channels onto cellulose and nitrocellulose paper in order to guide a sample 
across the appropriate pads storing the reagents required for an ELISA-like test.  
 First, dye tests were performed in order to characterize the dye flow functionality 
of the device itself in a single-sample format. This series of experiments verified that the 
design functioned as intended and was able to consistently and quickly route dye across 
the conjugate pad, detection pad, control pad, and down to the absorbent pad. These tests 
were performed with housing to further prototype the intended final design. The housing 
aided in layer alignment and provided uniform pressure across the device to ensure 
sufficient layer connectivity.  
 Further, the incorporation of reagents onto the paper-based device developed a 
successful three-step reaction, consisting of sample analyte binding to an HRP-conjugated 
detection antibody and a biotinylated capture antibody, using S100B as a model antigen 
for this test. The novel rotation of the device’s layers was used to open up new channels 
which were used as wash steps to further increase the sensitivity of the test, washing away 
unbound antibodies and antigens. The device was optimized for the ideal concentration of 
detection antibody and the limit of detection was determined. Through these optimization 
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experiments, an LOD of 11.83 pM was achieved, which is within the range of current 
ELISA tests on the commercial market.  
 This device, while also appropriate for use in hospitals and clinics, has potential to 
be used in developing nations which would not normally have access to this type of 
diagnostic technology. The test is portable, requires no external power, is cheap and easy 
to produce and use, and can be analyzed using cell phone camera images, meeting all of 
the ASSURED criteria put in place by the WHO, and making it a diagnostic device which 
has the ability to spread advanced diagnostics across the globe.  
 Overall, this thesis was able to demonstrate ELISA-like functionality on a novel 
paper-based design to achieve low limits of detection which by displaying a blue signal 
which can be converted into analyte concentration in order to accurately and quickly 
diagnose an ischemic stroke, resulting in faster treatment and better patient outcomes.  
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6. FUTURE DIRECTIONS 
 This section will describe potential future work on this paper-based ELISA-like 
device in order to further optimize the test and achieve lower limits of detection. 
 
 Signal Enhancement 
 The reason why ELISAs are able to be so sensitive is due to the signal amplification 
which is created by the reaction between HRP and TMB, turning the detection region blue, 
which can be read by a variety of software. The downfall of the paper-based system is the 
fact that reagents are left behind on the paper when travelling through the device. Further 
research could look into the effect of different blocking agents, wash reagents, and 
materials on the final color intensity. It is possible that the blocking of the device channels, 
and not just the conjugate and detection pads, would lead to a decrease in non-specific 
binding and therefore an increase in the signal intensity for a specific analyte concentration. 
A wash reagent other than PBS might yield better results by picking up and carrying more 
antibodies through the device. Finally, the material could be changed from cellulose to 
newer engineered options, such as the Whatman® Fusion 5, which is a proprietary 
membrane fabricated for fast wicking rates with no blocking required, due to it being a 
hydrophobic material [70]. 
 Additionally, the substrate of the enzymatic reaction should be investigated further 
to determine which substrate would have the best performance on the paper-based system. 
This thesis used a fast kinetic rate TMB from abcam® which made it difficult to obtain a 
picture of the accurate development of the blue color when accounting for the time taken 
to pipette the TMB onto seven sample pads. Either a different TMB solution could be 
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purchased or another HRP substrate entirely could be analyzed. In the same vein, the 
manner by which the HRP substrate is added onto the device could be optimized. It took 
approximately one minute to pipette the substrate onto each detection pad, which causes 
the development time of each sample to be different at the time that the photograph is taken 
for analysis. Perhaps the HRP substrate could be incorporated onto the device itself and 
resolubilized by the sample or from one pipetting step so that the substrate would reach 
and be able to react with the HRP on the detection pads at the same time.  
 
 Multiplex Assay 
 This device was only optimized to run a single sample to test for one analyte. In the 
future, it would be beneficial to be able to run several samples to test for several analytes 
in a multiplex fashion which would allow for incorporation of a protein panel onto the 
device for more accurate diagnosis of stroke, or other pathologies as desired. The same 
design as the one presented in this thesis could be used, only the antibodies on the conjugate 
pad and detection pad would need to be changed and optimized for each specific analyte 
to achieve a multiplex device. 
 
 Long-Term Reagent Storage 
 In order for the incorporation of the on-board reagents to be useful, they must have 
a proven long shelf life. Tests could be run in the future to determine how stable the on-
board reagents are with respect to time, humidity changes, and temperature changes that 
the device would undergo in transportation. Additionally, more development could be put 
into the housing unit utilized for this device. While the current assembly did provide a 
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platform to quickly run an assay, it left the sides open in order to allow for rotation of the 
top layer. This creates a non-sterile environment that would be required for the device. The 
top layer hanging outside of the housing also makes it susceptible to bending and ripping, 
rendering the device largely unusable. The housing should be designed to fully enclose the 
test while also allowing the user to rotate the top layer, perhaps by using a rotating wheel 
on the top side of the housing to “pull” the layer of paper in a circle as the wheel is rotated.  
 The possibilities for improvement on this device are varied and would only serve 
to create a better test for detection of stroke, or other conditions, and create better outcomes 
for at-risk patients around the world. 
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APPENDICES 
A. AutoCAD Dimensioned Drawings 
 
 
Figure 50. Dimensioned drawing of Holler (2016) device design 
 
 
Figure 51. Dimensioned drawing of Holler (2016) housing design 
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Figure 52. Dimensioned initial rotational outward flow design 
 
Figure 53. Dimensioned lateral motion pull strip design  
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Figure 54. Dimensioned outward flow design with four channels and a control pad 
 
Figure 55. Dimensioned outward flow design with three detection pad channels and three 
control pad channels 
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Figure 56. Dimensions of final design for one sample fluid flow validation test 
 
Figure 57. Dimensions of single sample device housing 
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Figure 58. Dimensioned nitrocellulose star design 
 
 
Figure 59. Dimensioned final design for the paper-based µPAD 
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Figure 60. Dimensioned final design for the paper-based µPAD housing 
 
 
 
 
 
 
 
 
 
B. Enzyme Assay Development 
Table XIV. High Concentration Dose Response - Trial 1 
High Concentration Set - Trial 1 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100000 88.232  100000 2.438025958 
10000 103.393  10000 2.685123513 
1000 93.70566667  1000 2.527237069 
100 90.57833333  100 2.476267052 
10 82.048  10 2.337237666 
1 100.0033333  1 2.629877926* 
0.1 35.67733333  0.1 1.581477598 
* Designates data which was removed for the corrected dose response data set 
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Table XV. High Concentration Dose Response - Trial 2 
High Concentration Set - Trial 2 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100000 33.40633333  100000 2.434179081 
10000 18.27966667  10000 1.784770818 
1000 27.551  1000 2.1828017 
100 17.21333333  100 1.738991686 
10 20.02833333  10 1.859843444 
1 13.01666667  1 1.558823109 
0.1 10.38566667  0.1 1.445870719 
 
Table XVI. High Concentration Dose Response - Trial 3 
High Concentration Set - Trial 3 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100000 34.835  100000 2.325112534 
10000 37.25633333  10000 2.417219299 
1000 38.45033333  1000 2.462638686 
100 39.491  100 2.502225322 
10 36.636  10 2.393622012 
1 23.98033333  1 1.9122044 
0.1 15.66166667  0.1 1.595764915 
 
 
Table XVII. Low Concentration Dose Response - Trial 1 
Low Concentration Set - Trial 1 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100 26.953  100 1.413347507 
10  --  10  -- 
1 19.87266667  1 1.253206071 
0.1 21.472  0.1 1.289379443 
0.01 18.88266667  0.01 1.230814466 
0.001 27.943  0.001 1.435739111* 
0.0001 20.563  0.0001 1.26881988 
* Designates data which was removed for the corrected dose response data set 
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Table XVIII. Low Concentration Dose Response - Trial 2 
Low Concentration Set - Trial 2 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100 26.061  100 1.991352311 
10 29.295  10 2.114372662 
1 22.433  1 1.853344323 
0.1 24.78933333  0.1 1.942978508 
0.01 23.72433333  0.01 1.90246624 
0.001 11.37333333  0.001 1.432638052 
0.0001 3.274666667  0.0001 1.124567299 
 
Table XIX. Low Concentration Dose Response - Trial 3 
Low Concentration Set - Trial 3 
Concentration 
(ng/ml) 
Average Color 
Intensity  
Concentration 
(ng/ml) 
Signal to 
Noise 
100 15.618  100 1.594103848 
10 21.97033333  10 1.835744627 
1 14.93733333  1 1.568211501 
0.1 34.84766667  0.1 2.32559437* 
0.01 27.50166667  0.01 2.046154822* 
0.001 6.589333333  0.001 1.250656185 
0.0001 8.294  0.0001 1.315501173 
* Designates data which was removed for the corrected dose response data set 
 
 
 
 
Table XX. Average of All Trials - Uncorrected 
All Trials Averaged 
Concentration (ng/ml) Signal to Noise 
100000 2.399105858 
10000 2.295704543 
1000 2.390892485 
100 1.952714621 
10 2.108164082 
1 1.795944555 
0.1 1.696844259 
0.01 1.726478509 
0.001 1.373011116 
0.0001 1.236296117 
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Figure 61. Uncorrected dose response graph 
The equation for the 4PL fit was determined, shown below, with an R2 value of 0.9340, 
indicating a good fit to the data.  
𝑦 = 2.751 + 8.271 ∗ 10`a − 2.7511 + O 𝑥0.0005394QY.cYca 
Table XXI. Average of All Trials - Corrected 
Corrected Trials Averaged 
Concentration (ng/ml) Signal to Noise 
100000 2.399105858 
10000 2.295704543 
1000 2.390892485 
100 1.952714621 
10 2.108164082 
1 1.62915788 
0.1 1.571094237 
0.01 1.566640353 
0.001 1.341647118 
0.0001 1.236296117 
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Concentration (ng/ml) Average Color Intensity 
100000 52.15777778 
10000 52.97633333 
1000 53.23566667 
100 35.98577778 
10 37.99553333 
1 32.37388889 
0.1 23.80561111 
0.01 23.36955556 
0.001 15.30188889 
0.0001 10.71055556 
 
 
Figure 62. Dose response of device for average intensity 
The equation for the 4PL fit was determined, shown below, with an R2 value of 0.9731, 
indicating a good fit to the data.  
𝑦 = 57.27 + 11.13 − 57.271 + O 𝑥2.573QY..(de 
 
